Photodecaging of a Mitochondria-Localized Iridium(III) Endoperoxide Complex for Two-Photon Photoactivated Therapy under Hypoxia.

International Journal of Nanomedicine Open Access Full Text Article REVIEW International Journal of Nanomedicine downloaded from https://www.dovepress.com/ For personal use only. Metal-Based Nanomedicines for Inducing Programmed Cell Death to Enhance the Efficacy of Cancer Immunotherapy Xiaoliang Cheng 1,2 , Nayoon Park 1,3 , Yonghyun Lee 1,3 1 College of Pharmacy, Ewha Womans University, Seoul, 03760, South Korea; 2Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061, People’s Republic of China; 3Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul, 03760, South Korea Correspondence: Yonghyun Lee, College of Pharmacy, Ewha Womans University, 52 Ewhayeodae-Gil, Seoul, 03760, South Korea, Email y.lee@ewha.ac.kr Abstract: Metal ions exert indispensable functions in various physiological processes, and metal ion homeostasis is needed in cells. Intracellular metal ion homeostasis is regulated by their efflux and influx across the cell membrane. Dysregulation of intracellular metallic ions can trigger programmed cell death (PCD). In recent years, metallic ions as potent immunomodulators and enhancers for cancer immunotherapy through modulating the immunosuppressive tumor microenvironment and triggering an immunostimulatory response have been extensively explored. The review focuses on the mechanism of PCD and immunomodulatory effects for various metal ions including iron, copper, calcium, zinc, and manganese, and provides a systematic overview of nanoparticles for delivering metallic ions or constructed of metals to realize PCD and enhance cancer immunotherapy. Finally, the prospect and challenges of clinic translation of metal-based nano-drug delivery systems in cancer therapy are outlined, and especially restriction of large-scale manufacturing and safety concern for clinic translation are further discussed. Keywords: metal ions, programmed cell death, cancer immunotherapy, immunomodulators, nanomedicine Introduction Cancer is a major health concern worldwide and a leading cause of mortality, and decreases average life expectancy in all countries.1 There were 18.5 million new cancer cases and 10.4 million cancer deaths estimated to occur globally in 2023, and there will be anticipated 30.5 million cases and 18.6 million deaths from cancer globally in 2050.2 Currently, chemotherapy, surgery, radiotherapy, targeted therapy and immunotherapy are the mainly therapeutic tactics for cancer. In recent years programmed cell death (PCD) has emerged as a potent approach to induce cell suicide, and it has drawn widespread attention as a research hotspot for cancer treatment. PCD is provoked by endogenous and exogenous factors that disturb cellular homeostasis and trigger cell suicide under dedicated molecular pathways,3,4 and multiple types of PCD such as ferroptosis, cuproptosis, calcicoptosis, apoptosis, pyroptosis, necroptosis, and PANoptosis have been elucidated and serve as targets for cancer therapy. Metal ions have essential effects on cell homeostasis, and increasing researches on the relationship of metal ions and tumor treatment have shown that several metal ions can induce PCD and provide novel insight for cancer therapy.5,6 PCD has been demonstrated to be related to modulate the immunosuppressive tumor microenvironment (TME) and trigger an immunostimulatory response.7,8 Cancer immunotherapy that harnesses the patient’s immune system to combat cancer cells has revolutionized cancer therapy. Over the past decades, cancer immunotherapy mainly including immune checkpoint inhibitors, vaccines, and immune cell therapies has been successfully implemented in the clinic and emerged as a novel therapeutic paradigm in solid and hematological malignancies.9 However, despite substantial achievements of cancer immunotherapy, patients experience low response, and a substantial proportion fail to achieve clinical benefit from cancer immunotherapy.10,11 As a prominent immune checkpoint blockade therapy, anti-programmed cell death protein 1 International Journal of Nanomedicine 2025:20 16055–16092 Received: 4 August 2025 Accepted: 22 November 2025 Published: 31 December 2025 16055 © 2025 Cheng et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Cheng et al (PD-1) and anti-programmed cell death ligand 1 (PD-L1) monoclonal antibodies have a low response rate of approxi­ mately 10–30%.12,13 Therapeutic potential of the combination of PCD and immunotherapy was proposed as a promising approach to improve the efficacy of caner immunotherapy.14,15 Metal ions, their targets and induced PCD, and mechanism of modulating immune response are summarized in Table 1. However, clinical utility of metal ions for eliciting PCD is prominently restricted by insufficient selectivity and targeting ability, toxicity, and dysregulation of systemic ion metabolism.16 Hence, the targeting delivery of metal ions to malignant cells is urgently needed to enhance therapeutic efficacy while minimizing adverse systemic effects. The past few decades have witnessed significant advancements of nanotechnology, and multiple nanopharmaceuticals such as Doxil, Abraxane, Marqibo, and Onivyde are approved and marketed for carcinoma therapy.17 Nanoparticles can improve the solubility of hydrophobic drugs, stability of unstable agents, modulate the pharmacokinetics and biodis­ tribution of loaded drug, realize passive targeting and active targeting via surface modification, reverse drug resistance, and minimize toxicity.17–19 A nanoparticle-based delivery system can achieve targeted delivery of metal ions, strength­ ening their PCD potency and minimizing off-target toxicity. Metal ions can be engineered into therapeutic nanostructures either by directly forming nanoscale particles or by being strongly coordinated into fabricated nanocarriers. This nanoformulation strategy not only enables passive tumor accumulation via the enhanced permeability and retention (EPR) effect but also allows further surface modification for active targeting. Therefore, the nanoparticles function not merely as delivery vehicles but as integral components that modulate biodistribution, prolong systemic circulation, and reduce off-target toxicity, ultimately leading to enhanced therapeutic efficacy. This review introduces the mechanism of PCD triggered by metal ions, the potency of PCD to modulate an immunosuppressive TME and induce an immunostimulatory response, and nanoformulations for integrating PCD and cancer immunotherapy. Relevant studies were retrieved from PubMed through title/abstract searches using combinations of “metal”, “nanoparticle”, and “immunotherapy”. As depicted in Scheme 1, the review focuses on ferroptosis, cuproptosis, calcicoptosis, and other PCD triggered by zinc and manganese. The interplay between PCD and cancer immunotherapy is discussed, and potential tactics to boost immunotherapy via PCD are presented. The review analyzes advantages and challenges in nanomedicine-loaded metal ions to trigger PCD and promote potency of immunotherapy, explores future research orientations, and proposes strategies to address existing challenges. Moreover, we expect to offer some rewarding suggestions and enlightenments for cancer immunotherapy. Nanoparticles for Ferroptosis and Cancer Immunotherapy Ferroptosis was first identified in 2012 by Dixon et al as a PCD pattern and is characterized by iron-driven lipid peroxidation.20 Ferroptosis has emerged as an important modulator in a scope of pathophysiological incidences encom­ passing oncology, ischemic organ injury, stroke, acute kidney injury, chronic kidney disease, cardiomyopathy, and neurodegenerative diseases.21 The importance of ferroptosis has piqued research interest of scholarly community, especially in cancer treatment. Despite the need to elucidate the physiological and pathological roles of ferroptosis, its mechanism of induction and function have been gradually revealed. Regulation Mechanism of Ferroptosis Ferroptosis is mediated by several primary pathways, encompassing iron metabolism, lipid peroxidation, and antioxidant mechanisms (Figure 1).22 It is crucial to determine if interactions among the aforementioned pathways affect cellular susceptibility to ferroptosis, posing profound implications for overall fitness. Iron is indispensable in physiological processes, is acquired by cells via intestinal absorption and degradation of erythrocytes, and plays a pivotal character in the pathway of ferroptosis. Extracellular ferric ion (Fe3+) preliminarily binds to transferrin (TF) to be internalized into cells via endocytosis by transferrin receptor 1 (TFR1).23 Fe3+ is reduced to Fe2+ after being transferred into the endosome by six-transmembrane epithelial antigen of prostate 3 (STEAP3), and then Fe2+ is liberated into the cytoplasm by divalent metal transporter 1 (DMT1). If the Fe2+ is not utilized, it can be preserved in mitochondria and cytoplasm in the form of a labile iron pool (LIP) or sequestered within a ferritin complex.24,25 Ferroportin is the sole protein responsible for exporting iron from the intracellular compartment to extracellular matrix, and it exerts a vital role in ferroptosis.26 Under pathological conditions, dysregulation in genes 16056 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 International Journal of Nanomedicine 2025:20 Table 1 Summary of Metal Ions, Their Molecular Targets, Induced Types of PCD, and Mechanisms of Immune Modulation Metal Target Induced PCD Mechanism of its Enhanced Cancer Immunotherapy Fenton reaction and generating ROS. Ferroptosis Induction of cell death for M2 macrophages, Treg cells and myeloid-derived Ion Fe suppressor cells and reversal of their immunosuppressive function; release of oxidation products and DAMPs; recovery of CD8+ T cell function; recruitment of antigen-presenting cells; release of immunomodulatory signals; mediating DCs maturation. Cu DLAT, Fe-S cluster proteins. Cuproptosis Enhancement of anticancer immunity via cGAS-STING pathway, activating tumor antigen-presentation and promoting DCs maturation; downregulation of WNT and PD-L1, enhancing infiltration and cytotoxicity CD8+ T cells; induction of ICD; elicitation of macrophages to M1 polarization; activation of CD8+ T cells and natural killer cells via major histocompatibility complex-I pathway. Ca Calcium/calmodulin-dependent protein phosphatase, necrosome complex, mitochondria. Calcicoptosis Stimulation of cytotoxic lymphocytes proliferation; activation of T lymphocyte-associated transcription factors; release of DAMPs; facilitation of exposure of calreticulin to deliver pro-phagocytic signals to myeloid cells; repolarization of TAMs to M1 phenotype and inhibition of M2 polarization. Zn Bax, Smad2, PIAS1, lysosome, ERK1/2, MTF1, CaMKKb/AMPK Apoptosis, lysozincrosis, Enhancement of an array of immune cells activity; alleviation of autophagy, necroptosis, ferroptosis and pyroptosis immunosuppressive TME via inhibiting release of inflammatory molecular and inflammatory response; enhancement of presentation and recognition of antigen; suppression of immune checkpoint protein expression; activation of cGAS-STING; release of DAMPs and interferon γ. System Xc− and excitatory amino acid transporter, Fenton and Haber-Weiss Ferroptosis, apoptosis, reactions, iron homeostasis, hypoxia-inducible factor-1 α /p53/SLC7A11, nuclear translocation of Yes-associated protein/transcriptional co-activator necroptosis Activation and functional regulation of immune cells, cGAS-STING pathway. with PDZ-binding motif, histone deacetylase, histone acetyltransferase, p53and p38-mitogen-activated protein kinases, mitogen and stress response kinase-1, STING-tumor necrosis factor. 16057 Cheng et al https://doi.org/10.2147/IJN.S558247 Mn Powered by TCPDF (www.tcpdf.org) Cheng et al Scheme 1 Metal ion-induced programmed cell death. encoding iron metabolism, particularly reduction in ferritin heavy chain 1 expression coupled with overexpression of TFR1, could trigger a substantial accumulation of intracellular iron to elicit a surge in reactive oxygen species (ROS) via the Fenton reaction.25,27,28 The elevated oxidative microenvironment can ultimately result in susceptibility of vulnerable cells to ferroptosis.25 Also, ferritinophagy which is regulated by nuclear receptor coactivator-4 (NCOA4) can activate ferroptosis by increasing intracellular iron density due to its involvement in ferritin breakdown.29 In addition, polyunsaturated fatty acids (PUFA) are essential components for cell membranes, and they are perceived as key stimuli for lipid peroxidation, which is a crucial process responsible for the onset of ferroptosis.30 PUFA undergoes esterification with long-chain acyl-coenzyme A (CoA), which is facilitated by acyl-CoA synthetase longchain family member 4 (ACSL4), leading to the production of PUFA-CoAs. Lysophosphatidylcholine acyltransferase 3 (LPCAT3) which is responsible for delivery of PUFA-CoAs into cell membrane phospholipids, plays a pivotal role in the subsequent peroxidation.31 Once integrated into phospholipids, the PUFA-CoA-integrated phospholipids are subjected to enzymatic oxidation by lipoxygenases (LOX) or autoxidation, and a cascade of biological reactions is initiated to generate the iron-dependent lipid peroxides that are a hallmark of ferroptosis.27,32 Once LOX, LPCAT3, and ACSL4 enzymes are overly active, lipid peroxidation occurs, resulting in oxidation of PUFA and accumulation of lipid peroxides. As displayed in Figure 1, eventually excessive lipid peroxides synergize with intracellular overloaded iron to cause a Fenton reaction, resulting in increased ROS levels, loss of structural integrity of the lipid bilayer, cytotoxicity, and death.27 System Xc−, a ubiquitous amino acid antiporter in phospholipid bilayers, regulates the exchange of cystine and glutamate at a stoichiometric ratio of 1:1 and is essential for cellular uptake of cystine.33,34 Within cells, cystine is converted into cysteine, which is an indispensable precursor for biosynthesis of glutathione (GSH).35 GSH is an endogenous antioxidant responsible for scavenging ROS via glutathione peroxidases (GPXs). Therefore, inhibition of this antiporter can lead to depletion of intracellular GSH and an increase of glutamate, which participates in ROS production after conversion into glutamine by glutaminase enzyme.36–38 GPX4 possesses the potency to degrade a range of lipid peroxides and block the detrimental cascade of lipid peroxidation, exerting a pivotal role in ferroptosis. A dramatic decline in the activity of GPX4 results in overproduced ROS and elevated oxidative stress, inducing ferroptotic cell death by the active ROS and lipid peroxides (Figure 1).39 Furthermore, p53 as a cancer suppressor protein can 16058 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al Figure 1 Summary of the metabolic pathway of ferroptosis. The intricate modulation of ferroptosis is regulated via several primary pathways, encompassing iron metabolism, lipid peroxidation, and antioxidant mechanisms. mediate cystine uptake by inhibiting the light chain SLC7A11 of the antiporter, influencing GPX4 activity and triggering ferroptosis.15 Interplay Between Ferroptosis and Cancer Immunotherapy Ferroptosis has been identified as an important player in regulation of immunosuppressive microenvironments and differentiation of immune cells, and its role in immunotherapy is becoming increasingly evident. Macrophages are important in tumor immunosuppression by supporting tumor development and progression and resistance to therapy. They can polarize into three phenotypes: unactivated M0, classically activated M1, and alterna­ tively activated M2 macrophages. M1 macrophages show high expression of iron-sequestering proteins such as ferritin and low expression of iron-exporting proteins such as FPN, store iron, and are resistant to ferroptosis, helping to fight cancer cells. On the contrary, M2 macrophages promote tumor cell proliferation and immune evasion by releasing iron, and they are susceptible to ferroptosis owing to high FPN and low ferritin expression.40 M2 macrophages can be repolarized into the M1 phenotype by ferroptosis inducers, and iron can promote M1 polarization under certain conditions.41,42 Similarly, Treg cells and myeloid-derived suppressor cells have an immunosuppressive role and antag­ onize ferroptosis through high expression of GPX4 or other proteins. Induction of ferroptosis in these cells may induce cell death and reverse their immunosuppressive function.42 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16059 Cheng et al Ferroptosis is accompanied by release of oxidation products, and damage-associated molecular patterns (DAMPs) such as high mobility group box 1 (HMGB1) can trigger inflammatory and immune responses during cell death.43,44 HMGB1 is one of the key elements required for activation of the innate and adaptive immune systems by binding to pattern recognition receptors.45 Recovery of CD8+ cytotoxic T cell function within the TME is an important factor determining response to cancer immunotherapy, and ferroptosis is a key metabolic regulator of CD8+ T cells activity.46 Ferroptotic cells liberate lipid cytokines as “find me” signals, which recruit antigen-presenting cells and other immune cells to the site.44 LOXs not only oxygenate esterified PUFAs as ferroptotic signals but also contribute to the release of oxidized lipid mediators as immunomodulatory signals from ferroptotic cancer cells, enhancing anti-tumor immunity.44 Arachidonate 15-lipoxygenase-derived lipid mediators mediate dendritic cells (DCs) maturation and regulate adaptive immune responses.47 Immune cells have an anti-tumor immunity function by releasing cytokines that trigger ferroptosis in cancer cells. For example, interferon γ released by CD8+ T cells and transforming growth factor-β released by macrophages decrease the expression of the antiporter system Xc−, followed by impaired uptake of cystine in cancer cells, promoting lipid peroxidation and ferroptosis in tumor cells.48,49 Nanoparticles for Ferroptosis to Enhance Cancer Immunotherapy Overload of iron can elicit tissue damage encompassing myocarditis that can progress to heart failure and neurological and neurodegenerative diseases.50,51 Hence, the targeted delivery of iron is indispensable to protect healthy tissues. Ferroptosis has been broadly applied as a novel strategy to enhance the efficacy of cancer immunotherapy. PD-1 and its ligand PD-L1 have emerged as important immune checkpoints in tumor treatment. Although neutralization of the negative immune checkpoints with anti-PD-1 or anti-PD-L1 antibodies has generated impressive progress in treatment of several types of cancer, such therapy is limited by a low response rate.12,13 As summarized in Table 2, various nanoparticles for delivery of iron ion have been designed and fabricated, aiming to augment the immune response against anti-PD-1 or anti-PD-L1 therapy by modulating activating immune cells. Cholesterol oxidase is responsible for catalysis of cholesterol to H2O2, and cholestenone enhances lipid peroxidation and ROS levels, promoting ferroptosis immune therapy.52 A novel nanozyme composed of iron metal-organic framework (MOF) for delivery of cholesterol oxidase and polyethylene glycosylation (Figure 2) 52 and catalytic hydrogel-loaded dimethyl maleic anhydride-modified cholesterol oxidase and a metalloporphyrin compound hemin with peroxidase-like activity53 were developed for integrated ferroptosis and immunotherapy. In combination with PD-1 or PD-L1 inhibitor, the nanodrug delivery system exerted a synergistic therapeutic effect. Jingbo Ma et al synthesized a multifunctional nanocomposite of sonosensitizer HMME, Fe3+, and tannic acid, and the nanocomposite consolidated the function of HMME for producing ROS and Fe3+ for induction of ferroptosis and ROS.54 More importantly, the nanocomposite could potentiate efficacy of immunotherapy by recruiting additional T cells and natural killer cells and promoting DCs maturation, and its combination with anti-PD-1 antibody could eradicate tumors. A hydrazide/Cu2+/Fe2+/indocyanine green coordinated nanoplatform was developed, the hydrazide-metal-sulfonate coordination significantly potentiated CD8+ T cell infiltration into tumor, and the nanoplatform and antibody against PD-1 synergistically eliminated the primary tumor and inhibited distant tumor metastasis and recurrence.55 A metalcoordinated carrier-free nanodrug was prepared by co-assembly of a natural product of ursolic acid, sorafenib, Fe3+, lowmolecular weight protamine, and epithelial cell adhesion molecule aptamer. The nanodrug induced immunogenic cell death (ICD) and augmented the immune response against PD-L1 via increasing infiltration of cytotoxic T cells to suppress tumor growth and distant metastasis.56 A tannic acid-Fe3+-coated 1,2-distearoyl-sn-glycero-3-phosphoethano­ lamine-N-[methoxy(PEG2000] (ammonium salt) micelle loaded with doxorubicin and anti-PD-L1 antibody enhanced anti-tumor immunity by activating CD4+ and CD8+ T cells and reducing the ratio of regulatory T cells to CD4+ T cells.57 Postoperative recurrence and metastasis especially brain metastasis dramatically deteriorate the survival rates for breast cancer sufferers. A core-shell nanoparticle of Fe MOF-encapsulated hollow mesoporous organosilica nanoparticles was proposed to deliver doxorubicin to prevent recurrence and metastasis.58 The nanosuspension synergistically improved doxorubicin chemotherapy, achieved remarkable ferroptosis by doxorubicin and iron ions, and significantly activated immune response including stimulating DCs, recruiting T cells, and facilitating antigen presentation. When 16060 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 International Journal of Nanomedicine 2025:20 Table 2 Iron-Based Nanomedicines for Triggering Ferroptosis to Enhance Cancer Immunotherapy 16061 Payload Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Iron MOF Cholesterol oxidase Iron MOF, PEG 220 Enhancement of ROS levels and inducement of LPO via depleting cholesterol and generating hydrogen peroxide, thereby promoting ferroptosis. iv Notable biosafety and synergistic therapeutic efficacy of the Fe MOF and PD-1 checkpoint blockade. [52] Hydrogel Cholesterol oxidase Oxydextran, hemin-chitosan Trigger of ferroptosis by combination of cholesterol oxidase and hemin, hence increased potency of anti-PD-L1 therapy. iv Inhibition of primary tumor growth and distant metastases. [53] Self-assembly HMME, Fe3+ Tannic acid, cholesterol, DSPEPEG2000, lecithin 73–83 Inducing apoptosis, ferroptosis, and ICD, and reshaping the TME and recruiting T cell infiltration. iv Almost eradication of tumors by integration of the selfassembly and PD-1 blockade. [54] Self-assembly Cu2+, Fe2+, indocyanine green 3,3′-dithiobis(propionohydrazide) 60 Photodynamic therapy and ferroptosis. iv Elimination of primary tumors and inhibition of distant tumor growth, lung metastasis and tumor recurrence by this self-assembly and PD-1 antibody. [55] Self-assembly Sorafenib, Fe3+ Ursolic acid, low-molecular weight protamine, epithelial cell adhesion molecule aptamer 137.1 Ferroptosis, chemotherapy and chemodynamic therapy. iv Significant suppression of tumor growth and distant metastasis by this self-assembly and anti-PD-L1. [56] Micelle Fe3+, doxorubicin Tannic acid, DSPE-PEG 18.17 Apoptosis and ferroptosis-mediated ICD. iv Considerable inhibition of tumor growth and improvement of anti-tumor immunity in combination with anti-PD-L1 antibody. [57] Nanosuspension Doxorubicin Fe MOF, mesoporous organosilica nanoparticles 150 Ferroptosis, chemotherapy, ICD. it Inhibition of postoperative recurrence and brain metastasis in integration with PD-1 antibody. [58] Core-shell nanoparticle Cholesterol derivative of dihydroartemisinin, pyropheophorbideiron 2-dioleoyl-snglycero-3-phosphate, 1,2-dioleyl-sn-glycero-3phosphocholine, cholesterol, DSPE-PEG 2000, Znpyrophosphate 90 Ferroptosis, immunostimulatory effect. iv Sensitization of non-immunogenic colorectal tumors to anti-PD-L1 therapy. [59] MOF Triptolide Tannic acid, Fe3+, folic acid modified bovine serum albumin 200 Ferroptosis, pyroptosis, release of large amounts of DAMPs. iv Effective inhibition of primary tumor and metastasis, and this effects were further enhanced by combination with PD-L1 antibody. [60] MOF Glucose oxidase MnO2, iron-based MOF, PEG 245 Ferroptosis, release of tumor immuneassociated antigens. iv Synergistic treatment of this MOF with aptamer-PD-L1. [61] Hybrid nanoparticle Sorafenib, antibody against transforming growth factor-β Fe3O4/Gd2O3 hybrid nanoparticles, arginine-glycine-aspartic dimer 15.4 Ferroptosis, release of DAMPs, promotion of DCs maturation, recruitment of CD8+ T cells. iv Inhibition of tumor growth and lung metastasis, and enhancement of anti-PD-1 efficacy. [62] (Continued) Powered by TCPDF (www.tcpdf.org) Cheng et al https://doi.org/10.2147/IJN.S558247 Carrier Type https://doi.org/10.2147/IJN.S558247 Cheng et al 16062 Table 2 (Continued). International Journal of Nanomedicine 2025:20 Carrier Type Payload Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Nanoparticle Glucose oxidase Cyclic arginine glycyl aspartate peptide, anisamide, polydopamine, Fe3O4 nanoparticle 150 Ferroptosis, photothermal therapy, ICD. iv Combined with PD-L1 antibody, favorable synergistic effectiveness against colorectal cancer. [63] Magnetic nanoparticle Sulfasalazine Mesoporous magnetic nanoparticles, platelet membrane 268.9 Ferroptotic cell death, repolarization of macrophages from M2 to M1 phenotype. iv The magnetic nanoparticles jointly with immunotherapy effectively inhibited the metastasis tumor growth. [64] Ultrasmall Fe nanoparticle None Fe core, iron oxide shell, iRGD peptide 3.8 Ferroptosis and ICD. iv Promotion of maturation of DCs and adaptive T cell response. Combined with anti-PD-L1 antibody, the nanoparticle significantly potentiated immune response and developed strong immune memory. [65] Ultrasmall Fe nanoparticle 131 I-labeled antibody against PD-L1 Ultrasmall iron nanoparticles, dopamine-fluorophenylboronic acid, bovine serum albumin 150 Ferroptosis, radiotherapy, ICD. iv Significant inhibitory effect on both primary and metastatic tumor growth. [66] Nanocrystal None Iron-palladium nanocrystal, polyvinylpyrrolidone 110 Autophagy-augmented ferroptosis, photothermal therapy, ICD. iv The nanocrystal synergized with PD-L1 antibody in suppressing both primary and distant tumors. [67] Abbreviations: iv, intravenous injection; it, intratumoral injection. Powered by TCPDF (www.tcpdf.org) Cheng et al Figure 2 A novel nanozyme composed of iron metal-organic framework nanoparticles delivering cholesterol oxidase and polyethylene glycosylation for integrated ferroptosis and immunotherapy. The nanozyme depleted cholesterol, produced excessive H2O2, and enhanced ROS and lipid peroxides levels to promote ferroptosis. Concurrently, the nanozyme augmented immunogenic cell death by reducing PD-L1 expression, promoting DCs maturation and M1 macrophage polarization, revitalizing exhausted CD8+ T cells and priming CD8+ T cells. In combination with PD-1 inhibitor the nanozyme exerted a synergistic therapeutic effect. used in conjunction with the PD-1 antibody, the nanosuspension could inhibit postoperative recurrence and brain metastasis of breast cancer. Zn-pyrophosphate core-shell nanoparticles for co-delivering a cholesterol derivative of dihydroartemisinin and pyropheophorbide-iron sensitized non-immunogenic colorectal tumor to anti-PD-L1 checkpoint blockade immunotherapy.59 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16063 Cheng et al A MOF was formed through the coordination between tannic acid and Fe3+ to deliver triptolide and was functiona­ lized by folic acid-modified bovine serum albumin.60 The nanoplatform triggered a potent systemic anti-tumor immune response by inducing ferroptosis and pyroptosis, and its combination with antibody against PD-L1 enhanced immu­ notherapy. Combined with aptamer-PD-L1 checkpoint blockade, iron-based MOF nanoparticles modified by MnO2, glucose oxidase, and polyethylene glycol (PEG) strengthened the tumor treatment efficiency.61 Fe3O4/Gd2O3 hybrid nanoparticles conjugated to arginine-glycine-aspartic dimers for loading sorafenib and antibody against transforming growth factor-β achieved cumulative ferroptosis through Fe3O4/Gd2O3 hybrid nanoparticlemediated Fenton reaction and sorafenib-mediated GSH synthesis blocking, and increased the potency of anti-PD1 therapy.62 Polydopamine, cyclic arginine glycyl aspartate, and anisamide-modified Fe3O4 nanoparticles enhanced cellular ferroptosis induced by Fe2+-mediated Fenton reaction via introducing glucose oxidase as a catalyzer for generation of H2O2, and in combination with antibody against PD-L1 the nanoparticles exhibited favorable synergistic effectiveness against colorectal cancer.63 A biomimetic platelet membrane camouflaged with Fe3O4 nanoparticles for delivery of sulfasalazine triggered ferroptotic cell death, and the biomimetic nanoparticles induced an anticancer immune response and efficiently repolarized immunosuppressive M2 macrophages to anti-tumor M1 phenotype, drastically enhancing the efficacy of PD-1 inhibitor.64 Ultrasmall body-centered cubic Fe nanoparticles with an Fe core approximately 2 nm in size and an iron oxide shell less than 0.7 nm were synthesized and further modified by the CRGDKGPD (iRGD) peptide. These nanoparticles could efficiently induce immunogenetic promotion of DCs maturation and adaptive T cell response. Combined with anti-PD-L1 antibody, the ultrasmall Fe nanoparticle-triggered ferroptosis significantly potentiated immune response and developed strong immune memory.65 Ultrasmall iron nanoparticles were functionalized by fluorophenylboronic acid to generate nitrogen-boronate complex with bovine serum albumin and 131I-labeled antibody against PD-L1. The ultrasmall nanoparticles were responsive to an increase of adenosine triphosphate in tumor owing to a relatively stronger affinity of ribose structure in adenosine triphosphate to fluorophenylboronic acid. The ICD caused by radiopharmaceutical therapy and ferroptosis combined with antibody against PD-L1 exhibited a strong anti-tumor immunity.66 A tetrapod spiky-like iron-palladium nanocrystal was engineered with decylamine as a coordinating ligand for coreduction of Fe and Pd species, and the surface of nanocrystal was modified with polyvinylpyrrolidone to improve its biosafety and biocompatibility. The nanocrystal induced lipid peroxide accumulation, promoted ferroptosis, and effec­ tively triggered the release of inflammatory cytokines (tumor necrosis factor-α, interleukin-6, and interleukin-1β) in macrophages, strengthening immunotherapy with antibody against PD-L1.67 Researches have reported synergism of iron nanoparticle-mediated ferroptosis and A2 adenosine receptor blocker,68 CD47 blocking antibody,69 or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) check point inhibitor70–72 for cancer immunotherapy. Nanoparticles for Cuproptosis and Cancer Immunotherapy In 2022, Tsvetkov et al discovered excessive copper-induced cell death as a distinct type of PCD from other modalities, and it was termed cuproptosis.73 Cuproptosis is featured by excessive accumulation of copper in cells, followed by mitochondrial dysfunction and toxic protein stress, ultimately leading to cell death. Tumor cells demonstrate increased metabolism processes and energy consumption, which are intricately associated with mitochondrial function. This indicates opportunities for cuproptosis as a novel target for eradication of tumor cells. Mechanism of Cuproptosis Copper is indispensable for regulation of redox-active enzymes, which are involved in various metabolism processes, signaling pathways, and biological functions.74 Intracellular copper homeostasis is tightly mediated by transporters, efflux protein, and enzymes responsible for conversion of Cu2+ to Cu+, and their coordinated processes maintain a precise balance of copper in cells. Disruption of copper homeostasis can lead to detrimental dysfunction of cells. Inadequate copper blunts normal metabolic activity, while excess copper produces cytotoxicity and ultimately results in cell death. The copper ionophore elesclomol translocates Cu2+ into cells dependent on mitochondrial respiration and disrupts copper homeostasis mediated by solute carrier family 31 member 1 (SLC31A1) which is previously called copper 16064 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al transporter protein 1 (CTR1) as copper import protein, and ATPase copper transporting α/β (ATP7A/B) as copper export protein (Figure 3).75 Accumulated copper in cells can directly combine with dihydrolipoamide S-acetyltransferase (DLAT), a lipoylated protein involved in the tricarboxylic acid cycle, to generate protein oligomers. Copper ions can undermine the synthesis of Fe-S cluster proteins, which are a crucial family of functional mitochondrial proteins involved in multiple process including cell energy metabolism, electron transfer, and substrate synthesis.76 These steps synergis­ tically result in proteotoxic stress response and ultimately lead to cuproptosis. Additional metabolic pathways mediating cuproptosis have been identified, among which ferredoxin 1 plays a pivotal role in protein lipoylation through integration into lipoic acid synthase and facilitation of its functional interplay with glycine cleavage system protein H.77 On the other hand, the ferredoxin 1 gene is responsible for encoding a small ironsulfur protein that converts Cu2+ to more toxic Cu+. However, Cu+ ions undermine the structure and function of ironsulfur clusters, resulting in their degradation (Figure 3). GSH, a cellular protector, can reduce the concentration of free Cu2+ and inhibit cuproptosis by binding to Cu2+ and generating a complex. The combination of GSH and Cu2+ is beneficial for maintenance of intracellular copper ion balance, and ferredoxin 1-mediated Cu2+ reduction reduces the detrimental influence of Cu+ on iron-sulfur cluster proteins, defending cells against copper-induced injury.78 Recent studies demonstrate that tumor suppressor p53 is also involved in modulation of cuproptosis. P53 is responsible for regulating transcription of GSH reductase to modulate biosynthesis and recycle GSH, and also is responsible for mediating the expression of genes linked to iron-sulfur proteins, regulating cellular GSH and iron-sulfur levels.79 Pathways mediating cuproptosis are illustrated in Figure 3. Relationship Between Cuproptosis and Cancer Immunotherapy Cuproptosis is believed to be closely associated with immune cell infiltration and has an important role in reprogramming the immunosuppressive microenvironment. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGASSTING) is demonstrated as a critical regulator of cancer immunity and facilitates various immune effector responses, and a cGAS-STING-mediated immune supportive microenvironment can hamper malignancy occurrence.80,81 Cuproptosis has been reported to enhance anticancer immunity through the cGAS-STING pathway, activating tumor antigen-presentation. The cGAS-STING signaling in DCs is triggered by cuproptosis-stimulated cancer cells, followed by release of inflammatory factors. In addition, combined cuproptosis inducers and PD-1 inhibitor synergistically Figure 3 Pathways mediating cuproptosis. Elesclomol binds to Cu2 + and transports it into intracellular compartments. Cu+ is primarily transported into cells via solute SLC31A1 previously called CTR1, while ATP7A/B are responsible for exporting copper ion. Excess intracellular copper primarily leads to cuproptosis through mitochondrial protein toxicity stress mediated by FDX1. This FDX1 reduces Cu2+ to Cu+, promotes lipidation and aggregation of enzymes involved in the mitochondrial tricarboxylic acid cycle particularly DLAT, and degrades iron-sulfur cluster proteins. (reproduced with permission from Xiaojie Zhang et al (2024). Copyright 2024 Springer Nature). International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16065 Cheng et al increases the circulating levels of CD45+CD8+ T cells, enhancing immunotherapy efficacy.82 Cuproptosis also signifi­ cantly stimulates mitochondrial DNA release to activate innate immunity via cGAS-STING signaling in vivo. Subsequently, secretion of type I interferon and expression of interferon-β are upregulated and DCs maturation is promoted. In addition, cuproptosis-associated innate immunity activates T-cell immunity.83 In vivo cuproptosis enhances infiltration of CD8+ T cells into tumor tissue, and cuproptosis potentiates the cytotoxicity of CD8+ T cells, which is realized by downregulating the WNT signaling pathway and PD-L1 expression.84 Cuproptosis triggered by a mitochon­ dria-targeted copper dithiocarbamate induces immunogenic death of cancer cells, leading to the release of DAMPs. The released DAMPs effectively elicit macrophages to M1 polarization and their migration towards target cell antigens, and secretion of relevant cytokines. The copper dithiocarbamate promotes antigen processing and presentation in cancer cells through the major histocompatibility complex-I pathway, activating CD8+ T cells and natural killer cells.85 Nanoparticles for Cuproptosis to Enhance Cancer Immunotherapy Copper overload in tissues leads to damages, including hepatotoxicity, nephrotoxicity, neurotoxicity, hemolysis, and cytotoxicity.86 Nanotechnology provides a potent approach to enhance anti-tumor immune response by regulating cuproptosis, overcoming the obstacles of current cancer immunotherapy and minimizing off-target toxicity. Nanodrugs for inducing cuproptosis to boost cancer immunotherapy are presented in Table 3. As depicted in Figure 4, a biomimetic cuproptosis amplifier was fabricated by Cu2+-regulated coordinative selfassembly of near-infrared II (1000–1700 nm) ultrasmall polymer dots and doxorubicin, followed by camouflaging of cancer cytomembrane. Overexpressed GSH in the TME reduced Cu2+ to Cu+, resulting in disassembly of the amplifier, photothermal therapy, chemotherapy, and cuproptosis. Cuproptosis elicited significant DCs maturation and infiltration of CD4+ and CD8+ T cells through ICD and reshaped the immunosuppressive TME via downregulated Tregs. The amplifier together with anti-PD-L1 antibody elicited a powerful anti-tumor immune response.87 A sodium alginate hydrogel incorporating elesclomol-Cu and galactose was developed to trigger persistent cuprop­ tosis, and the hydrogel abrogated radiation-induced PD-L1 upregulation, significantly enhancing the sensitization of cancer to radiotherapy and immunotherapy.88 A hydrogel composed of glycyrrhizic acid, copper ions, and celastrol was fabricated for synergistic cuproptosis and apoptosis, and the hydrogel repolarized tumor-associated macrophages (TAMs) into M1 phenotype, induced T cell proliferation and infiltration, activated antigen presentation, and upregulated PD-L1 expression. Upon co-administration with PD-L1 antibody, the hydrogel synergistically alleviated both primary and metastatic tumors.89 Yiming Xu et al decorated lung cancer cytomembrane onto glucose oxidase-loaded copper-layered double hydroxide nanoparticles to generate an intelligent biomimetic nanodrug. The nanodrug significantly induced cuproptosis and PD-L1 upregulation in lung cancer cells and sensitized the therapeutic potency of antibody against PD-L1.90 An Escherichia coli and Cu2O nanoparticle microbial nanohybrid was fabricated by electrostatic interaction through simple mixing, and the nanohybrid reversed the immunosuppressive microenvironment by inducing DCs maturation and T cell activation. Upon synergism with PD-1 antibody, the nanohybrid inhibited relapse and metastasis of colon tumors.91 Tumor-targeting peptides RGD coated hollow mesoporous copper sulfide nanoparticle for delivery of the nitric oxide donor L-Arginine induced cuproptosis, promoted immune cell infiltration and activation, and converted “cold” tumors into “hot” ones. In addition, their combination with antibody against PD-L1 significantly enhanced the immunotherapy response rate in triple-negative breast cancer.92 A Cu2+-based MOF loaded with the copper ionophore elesclomol and surface modified with PEG polymer was developed for cuproptosis induction to increase anticancer immune response, and combing the MOF with PD-L1 antibody reshaped the immunosuppressive TME to an immunogenic milieu, significantly inhibiting tumor growth.93 A ROS-sensitive polymer was designed and used to encapsulate elesclomol and copper. The micelle triggered cuproptosis, promoted DCs maturation and CD8+ cell infiltration, and reprogrammed the TME. Moreover, the micelle dramatically increased PD-L1 expression and effectively enhanced the response rate to anti-PD-L1 therapy.94 Copper oxide nanoparticles were encapsulated into the PEG-modified copper ionophore elesclomol, and the nanodrug triggered an immune response and reshaped the immunosuppressive microenvironment by increasing the number of tumorinfiltrating lymphocytes and secretion of inflammatory cytokines. In addition, combining the nanoparticles and anti- 16066 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 International Journal of Nanomedicine 2025:20 Table 3 Copper-Based Nanomedicines for Inducing Cuproptosis to Boost Cancer Immunotherapy Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Self-assembly Doxorubicin Near-infrared II ultrasmall polymer dots, tumor cell membranes 122 Cuproptosis, ICD, photothermal therapy and chemotherapy. iv Elicitation of boosted immune response, promotion of T cells infiltration, and enhanced anti-tumor effects on primary and distant tumors together with PD-L1 antibody. [87] Hydrogel Elesclomol-Cu, galactose Sodium alginate None Cuproptosis, radio-immunotherapy. it Downregulation of PD-L1, sensitization of tumor to radiotherapy and immunotherapy, and prolonged survival of mice bearing both local and metastatic tumors in combination of PD-L1 antibody. [88] Hydrogel Cu2+, celastrol Glycyrrhizic acid None Chemo-dynamic therapy, apoptosis, cuproptosis. it Co-administration with PD-L1 antibody, mitigation of both primary and metastasis tumors. [89] Nanoparticle Glucose oxidase Copper-layered double hydroxide nanoparticle, lung cancer cell membrane 93.93 Cuproptosis, cancer starvation, upregulation of PD-L1. iv Sensitization of efficacy of PD-L1 antibody, and substantial inhibition of both subcutaneous and lung metastasis tumors. [90] Nanohybrid None Escherichia coli and Cu2O nanoparticles ~1600 Ferroptosis, cuproptosis, photothermal therapy, immunosuppression reversion. iv Reversal of cancer immunosuppression by triggering DCs maturation and T cell activation. [91] Hollow mesoporous nanoparticle L-Arginine RGD peptide, hollow mesoporous CuS nanoparticle 300 Mild photothermal therapy, cuproptosis, generation of peroxynitrite anions, ICD. iv Promotion of immune cell infiltration and activation, and conversion of “cold” tumors into “hot” ones. [92] MOF Copper ionophore elesclomol Cu2+-based MOF, PEG 171.9 Cuproptosis, ICD. iv Conversion of immunosuppressive tumor to immunogenic one and effective inhibition of tumor growth by combined MOF and PD-L1 antibody. [93] Nanoparticle Elesclomol and Cu ROS-sensitive polymer PHPM 62.8 Cuproptosis, increment of PD-L1 expression in tumor cells, transformation of immune “cold tumors” into “hot tumors”. iv Reprogramming TME and triggering an effective antitumor immune response together with PD-L1 antibody. [94] Nanoparticle Copper ionophore elesclomol Copper oxide nanoparticles, PEG 112 Cuproptosis, ICD, release of DAMPs. iv Remodeling immunosuppressive TME and significant inhibition of tumor growth in combination with PD-1 antibody. [95] Nanoparticle Copper, erastin 1,2-dioleoyl-sn-glycero-3phosphocholine, 1,2-dioleoylsn-glycero-3-phosphate, cholesterol,DSPE-PEG2000 146.8 Ferroptosis, cuproptosis, ICD. iv Co-administration with PD-L1 antibody, potent regression of tumor and prevention of tumor metastasis. [96] Nanoparticle Celastrol, Cu DSPE-PEG2000 110 Cuproptosis, ICD. iv Combing with PD-L1 antibody, effective eradication of metastatic tumors in lung metastasis model. [97] 16067 Payload (Continued) Powered by TCPDF (www.tcpdf.org) Cheng et al https://doi.org/10.2147/IJN.S558247 Carrier Type https://doi.org/10.2147/IJN.S558247 Cheng et al 16068 Table 3 (Continued). Carrier Type Payload Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Nanoparticle Copper Aloe emodin, PEG2000DSPE-folic acid 120 Cuproptosis, photodynamic immunotherapy iv Induction of DCs maturation, promotion of lymphocyte infiltration, transformation of “cold tumors” into “hot tumors”, and significant enhancement of immune checkpoint blockade efficacy. [98] MOF Pyruvate dehydrogenase kinase 1 siRNA Poly (2-(N-oxide-N,Ndiethylamino)ethyl methacrylate), copper-based MOF 147.4 Cuproptosis, ICD, upregulation of membrane-associated PD-L1 expression and soluble PD-L1 secretion. ih Conversion of immunosuppressive TME to immuneactivating environment and inhibition of metastatic lung tumor growth. [99] Nanoparticle Disulfiram Cu2+-chitosan shell and low molecular weight heparintocopherol succinate core 186.9 Cuproptosis, activation of cGASSTING pathway to increase innate and adaptive immunity, reversal of immunosuppressive TME. ih Collaborated with PD-L1 antibody, provocation of more powerful anti-tumor immunity to inhibit occurrence of lung metastasis. [100] International Journal of Nanomedicine 2025:20 Abbreviations: iv, intravenous injection; it, intratumoral injection; ih, inhalation. Powered by TCPDF (www.tcpdf.org) Cheng et al Figure 4 Schematic illustration of the biomimetic self-assembly of cuproptosis amplifier for synergistic tumor immunotherapy. (a) Preparation of the near-infrared II semiconducting polymer and the biomimetic cuproptosis amplifier (PCD@CM). (b) Near-infrared-II fluorescence/photoacoustic imaging-mediated chemotherapy and photothermal amplified cuproptosis, provoking anti-tumor immunotherapy combined with immune checkpoint blockade mediated by anti-PD-L1 antibody. , downregulation; , upregulation. (reproduced with permission from Yeneng Dai et al (2024). Copyright 2024 Elsevier). PD-1 therapy substantially increased the anticancer potency.95 A novel bifunctional nanoparticle comprising a core of 1,2-dioleoyl-sn-glycero-3-phosphocholine, cholesterol, PEG-coated copper ions and peroxide, and an erastin shell was constructed for synergistic cuproptosis and ferroptosis. Erastin of anti-Warburg potency sensitized cancer cells to cuproptosis, resulting in ICD, enhanced antigen presentation, increased proliferation and infiltration of T cells, and upregulated PD-1 expression. When combined with PD-L1 antibody, the nanoparticles supported T cells to mediate cancer regression and prevent metastasis.96 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16069 Cheng et al Self-amplified cuproptotic nanoparticles have been produced using the natural product celastrol as a versatile copper ionophore and scavenger for GSH to amplify cuproptosis, and the celastrol-copper complex was encapsulated by PEG. The self-amplified cuproptotic nanoparticles evoked ICD to trigger a potent immune response, and their combination with antibody against PD-L1 effectively eradicated metastatic tumors in an animal model.97 Aloe emodin, a natural compound found in a plant, was chelated to copper ions and self-assembled into nanoparticles under modification with PEG and folic acid conjunction. The nanoparticles elicited maturation of DCs, infiltration of lymphocytes, transformation of “cold tumors” into “hot tumors”, and potently increased the efficacy of immune checkpoint blockade.98 An inhalable poly (2-(N-oxide-N,N-diethylamino) ethyl methacrylate)-coated copper-based MOF loaded with pyr­ uvate dehydrogenase kinase 1 siRNA, which blocks the copper efflux protein ATP7B, was fabricated to trigger cuproptosis and promote immunotherapy. The nanodrug triggered ICD and upregulated membrane-associated PD-L1 expression and soluble PD-L1 secretion, demonstrating synergism with the PD-L1 antibody.99 Another inhalable nanoparticle was composed of a Cu2+-chitosan shell and a low-molecular-weight heparin-tocopherol succinate core and was loaded with disulfiram, which chelated with Cu2+ to suppress ATP generation and Cu+ transporter ATP7B expression. The inhalable nanoparticles enhanced cuproptosis and activated the cGAS-STING pathway to increase innate and adaptive immunity, and strong anticancer immunity was realized by combing with PD-L1 antibody.100 Nanoparticles for Calcicoptosis and Cancer Immunotherapy Calcium overload is generally featured by excessive accumulation of Ca2+ in cytoplasm or mitochondria. Under endoplasmic reticulum (ER) stress, the capability of cells to manipulate Ca2+ homeostasis is undermined. Ca2+ is sustainably released from the ER, which is the primary intracellular calcium ion pool, and cytosolic Ca2+ concentration is increased, followed by transport of Ca2+ into mitochondria, leading to mitochondrial Ca2+ overload.101 In some conditions, Ca2+ overload can cause cell death through a distinct mechanism defined as calcicoptosis, which offers a novel strategy for cancer treatment. Mechanism of Calcicoptosis ER Ca2+ channel protein transmembrane and coiled-coil domains 1 (TMCO1) exert an important function in regulating calcium overload and maintaining calcium homeostasis, and inhibiting TMCO1 expression disrupts intracellular calcium homeostasis.102 Participation of calcium in signaling among organelles determines the fate of cells and influences cell survival or programmed death. During ER stress such as excessive misfolded protein, DNA damage, oxidative stress, and pro-apoptotic signals, Ca2+ is liberated into cytoplasm to activate dependent proteases approaching the ER. The activated proteases can trigger and release Caspase-12 into cytoplasm and activate the calcium/calmodulin-dependent protein phosphatase, which is respon­ sible for dephosphorylation of the pro-apoptotic protein Bad, followed by release of cytochrome C to induce apoptosis.­ 103 A previous study has uncovered a synergistic effect between cellular oxidative stress and calcium overload, ultimately leading to cell death.104 Figure 5 schematically illustrates the mechanism of calcicoptosis. Necroptosis, which is responsive to death stimuli such as tumor necrosis factor α and Fas ligand, also depends on calcium homeostasis. Upon reorganization of the ligand by the receptor on cell membrane, receptor-interacting protein kinase (RIPK)-1 forms a necrosome complex with RIPK3 and mixed lineage kinase domain-like protein (MLKL). The necrosome triggers mitochondria to produce ROS, leading to cell death.105 The formation of a necrosome complex results in increased cytosolic calcium, followed by trimerization of MLKL and its translocation to the cell membrane. The MLKL enables influx of calcium into the cell and intensifies necroptosis in a feedback manner through interaction with the transient receptor potential melastatin 7 channel.106 Calcium acts as a modulator of necrosome complex proteins and cell death. Necrosis which is featured by rapid disintegration of cytoarchitecture, release of cellular contents, and an inflamma­ tory reaction is also triggered by calcium overload.107,108 Increased intracellular calcium concentration is induced by activation of transient receptor potential cation channel subfamily V member 1 to trigger cell death mainly through a necrotic pathway.109 The release of Ca2+ from ER into the cytoplasm and their accumulation in mitochondria lead to Ca2+ 16070 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al Figure 5 Schematic illustration of the mechanism of calcicoptosis. Under endoplasmic reticulum stress, Ca2+ is sustainably released from the endoplasmic reticulum, which is the primary intracellular calcium ion pool, and cytosolic Ca2+ concentration is increased and transported into mitochondria, leading to mitochondrial Ca2+ overload. In some conditions, Ca2+ overload can cause cell death through a distinct mechanism defined as calcicoptosis, which offers a novel strategy for cancer treatment. (reproduced with permission from Jie Gu et al (2024). Copyright 2024 Springer Nature). overload and opening of mitochondrial permeability transition pores, resulting in swelling, mitochondrial rupture, and release of their contents to induce necrosis.110 Calcium ions also exert an important character in regulation of other PCD such as ferroptosis, pyroptosis, autophagy, and paraptosis.110 Precise regulation of calcium signaling in cells is a powerful tool in cancer therapy. Relationship Between Calcicoptosis and Cancer Immunotherapy The regulation of intracellular calcium ions plays an essential role in immune cell activation, and targeting increased intracellular calcium ions can significantly stimulate the proliferation of cytotoxic lymphocytes.111 Moreover, activation of T lymphocyte-associated transcription factors, for example, nuclear factor of activated T cells, nuclear factor kappa-B, and c-Jun N-terminal kinase, are heavily dependent on excessive accumulation of intracellular calcium ions.112,113 Necroptosis is dependent on calcium homeostasis and triggers cells to release DAMPs that promote an anti-tumor immune response.114 HMGB1 is liberated from cells undergoing necrosis triggered by calcium overload, acting as a DAMP to activate macrophages and DCs in the TME.115 Further, calcium overload facilitates the exposure of calreticulin localized in ER to deliver intensive pro-phagocytic signals to myeloid cells.116,117 Previous researches have demonstrated that the concentration of calcium ion in macrophages might be closely associated with their phenotype. Increase in cytoplasmic calcium ions can activate p38 and nuclear factor kappa-B for repolarizing TAMs to the M1 phenotype and stimulate transcription factor EB for reprograming the metabolism of TAMs.118 Excessive ROS and lipid peroxidation triggered by calcium overload through the ROS/p38-MAPK/diacylglycerol-O-acyltransferase 1 pathway are also speculated to inhibit M2 macrophage polarization.119 Nanoparticles for Calcicoptosis to Enhance Cancer Immunotherapy Hypercalcemia results in clinical manifestations such as nausea, renal dysfunction, nephrocalcinosis, vascular calcifica­ tion, and cardiac arrhythmias.120 Therefore, the targeted delivery with nanomedicine can enhance efficacy and minimize toxicity. Nanoparticles for delivering Ca2+ or calcium-based nanovehicles to strengthen cancer immunotherapy are illustrated in Table 4. Calcium carbonate-based nanoparticles are the most widely used vehicle for calcium overload therapy. pH-responsive and catalase-delivered calcium carbonate nanoparticles have been constructed to reshape the TME for enhanced immune checkpoint blockade. CaCO3 nanoparticles reacted with protons in an acidic TME to reprogram it, and the released Ca2+ led to overload in cancer cells, followed by liberation of DAMP signals and repolarization of M2 TAMs to the M1 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16071 https://doi.org/10.2147/IJN.S558247 Cheng et al 16072 Table 4 Calcium-Based Nanomedicines for Inducing Calcicoptosis to Strengthen Cancer Immunotherapy Carrier Type Payload Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Nanoparticle Catalase Calcium carbonate nanoparticle 187 Normalization of pH and relieve of hypoxia in TME, Ca2+ overload triggered release of DAMPs, enhanced tumor antigen presentation by DCs, repolarization of M2 TAMs to M1 phenotype. it Together with PD-1 antibody, effective evocation of local and systemic anti-tumor immune responses, and inhibition of treated and distant tumors growth. [121] Hydrogel Bufalin CaCO3 nanoparticles, alginate hydrogel None Direct anticancer efficacy, Ca2+ overloadtriggered pyroptosis, upregulation of PD-L1. it Potential evocation of higher immune response, promotion of DCs maturation, CD8+ T cell maturation and infiltration, and generation of a synergistic effect together with PD-1 antibody. [122] Core-shell nanostructure None Cu2O core, CaCO3 shell, hyaluronic acid 167.6 Photothermal, photodynamic, chemodynamic and calcium-overload mediated therapy iv Reprogramming macrophages from M2 to M1 phenotype and initiating a vaccine-like immune effect, which intensifies immune responses for anti-CD47 antibody to inhibit distant metastasis and recurrence. [123] Nanoparticle Doxorubicin, erianin CaCO3 nanoparticle, poly(D, 120 Calcium overload, chemotherapy, metabolic remodeling, ferroptosis, apoptosis, ICD. iv Reversal of unfavorable TME and enhancement of PD-L1 antibody immunotherapy. [124] L-lactide-co-glycolide)−PEG International Journal of Nanomedicine 2025:20 Nanoparticle Carbonic anhydrase inhibitor CaCO3 nanoparticles, 1, 2dioleoyl-sn-glycero-3phosphate sodium, 1,2Dipalmitoyl-sn-glycero-3phosphorylcholine, cholesterol, DSPE-PEG5000 115.5 Reversal of acidic tumor microenvironment and the increase of intracellular H+, calcium overload, radiotherapy-induced ICD and DCs maturation, repolarization of macrophages from M2 to M1 phenotype. iv Combined with PD-L1 antibody, effective inhibition the growth of distant/ orthotropic tumors. [125] Nanoparticle Curcumin CaCO3 and MnO2 nanoparticles, B16F10 cell membrane 392.70 Neutralization of protons and attenuation of cellular acidity, ICD, calcium overload, relief of hypoxia, activation of cGAS-STING pathway, induction of macrophage polarization and DCs maturation iv Enhanced anti-tumor responses of antibody against PD-1. [126] Colloidosome Catalase, PD-1 antibody CaCO3 nanoparticle, sodium n-octanoate, poly(D,L-lactideco-glycolide) acid 100 Modulation of tumor acidity and hypoxia, reversal of tumor immunosuppression. it Significant potentiation of both immune checkpoint blockade and CAR-T cell immunotherapies toward solid tumors. [127] Self-assembly Ca2+, GSK2837808A Hyaluronic acid-catechol, PEG-polyphenol, and PEGIR780 122.4 Suppression of aerobic glycolysis and creation of high-glucose and low-lactate conditions, calcium overload, release of DAMPs for activation and tumor infiltration of CD8+ T cell. iv Combining with CTLA-4 antibodies, effective inhibition of both primary and distant tumors. [128] Powered by TCPDF (www.tcpdf.org) International Journal of Nanomedicine 2025:20 Ca2+ Zr, tetrakis-(4carboxyphenyl)-porphyrin ~200 Calcium overload, photodynamic therapy, ICD, release of tumor-associated antigen, promotion of DCs maturation and CD8+ T cells activity. iv Co-administrated with PD-1 antibody, prominent elimination of primary tumor and obvious antimetastasis effect. [129] Core-shell nanoparticle None TiO2 core, CaP shell, poly (acrylic acid) Diameter 73.40, length 57.73 Calcium overload, sonodynamic therapy, ICD, enhanced T-cell recruitment and infiltration. iv In conjunction with PD-1 antibody, elicitation of systemic anti-tumor immunity, regression of distant tumors and lung metastasis. [130] Nanoparticle None Calcium hydroxide nanoparticle, layer of silica, PEG, anti-CD205 antibody 245.2 Activation of nuclear factor of activated T cells and the nuclear factor kappa-B by elevated cytosolic calcium, and promotion of expression of costimulatory, antigenpresenting and pro-inflammatory molecules. it Enhanced anti-tumor immune response and augmented efficacy for radiotherapy, chemotherapy and immunotherapy. [131] Nanoparticle CaO2 Mesoporous silica nanoparticles, mitochondrial photosensitizer N770 462.7 Calcium overload, phototherapy, alleviation of immunosuppressive microenvironment, ICD. iv Together with PD-L1 antibody, eradication of orthotopic and distant tumors, and potentiation of systemic anti-tumor immunity. [132] Nanoparticle None CaO2 nanoparticle, ultrasmall CuS-MnO2, hyaluronate acid 180 Calcium overload, photodynamic therapy, ICD, elicitation of adequate DAMPs, reprogramming tumor immunosuppression by transforming TAMs to M1 phenotype. iv Combined with PD-L1 antibody, effective increment of matured DCs, M1 macrophages and CD8+ T cells in tumor, and vigorous immune memory against tumor metastasis. [133] Nanoparticle None Manganese-doped calcium sulfide nanoparticles, PEG 80 Calcium overload-regulated pyroptosis and cGAS-STING pathway, inhibition of energy metabolism, mitochondrial dysfunction, activation of DCs, H2S enhanced innate and adaptive immune responses. it Integrated with PD-1 immunotherapy, activation of a strong anti-tumor immune response and synergistic anti-tumor effect. [134] Nanoparticle None Calcium sulfide nanoparticles, poly(acrylic acid), zinc protoporphyrin 127.5 Ca2+ overload, Ca2+-dependent cell death, activation of anti-tumor immunity, suppression of antideath effect. iv Co-administrated with PD-1 antibody, marked eradication of primary tumor and distant metastases, and fabrication of immunological memory to arrest tumor metastasis and recurrence. [135] Abbreviations: iv, intravenous injection; it, intratumoral injection. 16073 Cheng et al https://doi.org/10.2147/IJN.S558247 MOF Powered by TCPDF (www.tcpdf.org) Cheng et al phenotype, enhancing tumor antigen presentation by DCs. Consequently, the CaCO3 nanoparticles triggered a T cellregulated immune response that can combine with antibody against PD-1 to stimulate local and systemic immune responses, suppressing growth of both primary and metastatic tumors.121 A calcium carbonate nanoparticle hydrogel was loaded with the anticancer drug bufalin as an inhibitor of Na+/K+-ATPase to increase intracellular Ca2+ level. The resulting pyroptosis enhanced the efficacy of PD-1 antibody to induce an inflammatory TME, achieving synergistic potency in stimulating an immune response.122 A core-shell Cu2O and CaCO3 nanocomposite that was responsive to acidic pH and H2S sulfuration was used for photothermal, photodynamic, chemodynamic, and calcium-overloadmediated therapy, reprogrammed TAMs of the M2 phenotype to that of M1, and initiated a T cell-regulated immune response. Combined CD47 blockade and the nanocomposite induced a strong immune response, effective ablation of the primary tumor, and inhibition of cancer recurrence and metastasis.123 Zheng et al used a modified double emulsion method to encapsulate doxorubicin and erianin into CaCO3 nanoparticles. The multifunctional nanoparticles effectively elicited calcium overload and oxidative stress damage to activate hybrid ferroptosis and apoptosis pathways and led to prominent ICD. Additionally, the CaCO3 nanoparticles synergistically amplified the potency of anti-PD-L1 antibody.124 CaCO3 nanoparticles were utilized to deliver a carbonic anhydrase inhibitor that improved the sensitivity of cancer to radiotherapy and further were modified with liposomes. The nanoparticles induced cellular calcium overload, strength­ ened ICD triggered by radiotherapy and DCs maturation, and repolarized macrophages from pro-tumor M2 to anti-tumor M1 phenotype, amplifying systemic anti-adaptive immunity. With PD-L1 antibody, the efficacy of CaCO3 nanoparticles plus radiotherapy was increased, resulting in longer survival time.125 A pH-sensitive nanoparticle for co-delivery of curcumin as a Ca2+ enhancer, CaCO3 and MnO2 were encapsulated by a cancer cell membrane, and the released Ca2+ triggered calcium overload and ROS production in mitochondria and ER, leading to ICD. In addition, the nanoparticle repolarized macrophages and induced DCs maturation via antigen presentation and enhanced immune responses of the anti-PD1 antibody.126 Calcium carbonate nanoparticles encapsulating catalase assembled colloidosomes could activate strong anticancer immunity to significantly amplify the efficacy of co-loaded antibody against PD-1 and dramatically reinforce the therapeutic outcome of epidermal growth factor receptor-expressing CAR-T cells.127 Hyaluronic acid-catechol, PEG-polyphenol, and PEG-IR780 self-assembled into nanoparticles for carrying Ca2+ and lactate dehydrogenase A inhibitor GSK2837808A. Satisfying glucose nutrition required by CD8+ tumor-infiltrating lymphocytes and destabilizing regulatory T were realized by inhibiting lactate dehydrogenase A, and further CD8+ T cell activation and tumor infiltration were promoted by the released DAMPs triggered by Ca2+ overload in mitochondrion and amplified mitochondrial dysfunction. Cooperating with CTLA-4 antibodies further enhanced therapeutic efficacy.128 Yu et al constructed a mineralized porphyrin MOF encapsulating calcium phosphate for amplified cell damage caused by calcium overload and photodynamic therapy. The MOF could induce cell immunogenic death to liberate tumorassociated antigen, promote DCs maturation and enhance anticancer activity of CD8+ T cells, and co-administration with PD-1 antibody demonstrated prominent elimination of primary tumor and obvious inhibition for metastasis.129 A transformable TiO2 core and CaP shell nanosonosensitizer combining ROS generation and intracellular calcium overload substantially strengthened ICD, T cell recruitment, and infiltration into the immunogenic cold tumor. In combination with PD-1 antibody, the nanosonosensitizer regulated sonodynamic therapy-triggered systemic anticancer immunity.130 Calcium hydroxide nanoparticles coated with a layer of silica and further conjugated with anti-CD205 antibody were designed for targeted delivery to DCs. The elevated cytosolic calcium triggered nuclear factor of activated T cells and the nuclear factor kappa-B signaling pathway, followed by enhanced anticancer immune response and increased efficacy of anti-PD-L1 antibody.131 The mitochondrial photosensitizer N770 conjugated mesoporous silica nanoparticles for delivery of CaO2 achieved phototherapy, and calcium overload triggered ER stress and mitochondrial damage, and relieved the immunosuppressive microenvironment. Moreover, mesoporous silica nanoparticles together with antibody against PD-L1 significantly potentiated systemic anti-tumor immunity.132 Bovine serum albumin-templated ultrasmall CuS-MnO2 nanoparticles were adhered to the surface of CaO2 nanoparticles via surface electrostatic interaction, and the nanoparticles were wrapped with hyaluronate acid. A large mass of O2 and Ca2+ produced by CaO2 nanoparticles strengthened photo­ dynamic therapy and Ca2+ overload separately, amplifying ICD. Combing the nanoparticles with antibody against PD-L1 achieved enhanced immunotherapy efficacy and long-term protection.133 16074 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al PEG-decorated manganese-doped calcium sulfide nanoparticles rapidly liberated Ca2+, Mn2+, and H2S responding to a TME, and the released H2S was a crucial synergist for Ca2+ in pyroptosis-triggered calcium overload by disrupting intracellular calcium homeostasis and interfering with oxidative phosphorylation pathways (Figure 6). Via activation of calcium overload-regulated pyroptosis and the cGAS-STING pathway, manganese-doped calcium sulfide nanoparticles stimulated both innate and adaptive anticancer immune response and boosted the efficacy of anti-PD-1 therapy.134 A porous poly(acrylic acid) stabilized CaS nanoparticles delivering zinc protoporphyrin as a messenger amplifier resulted in Ca2+-dependent tumor immunogenic death and triggered release of tumor-associated antigens as an in situ vaccine to activate the immune response. Integration of CaS nanoparticles and anti-PD-1 antibody fabricated immune memory to produce long-term immunity against tumor metastasis and recurrence.135 Zinc-Based Nanoparticles and Cancer Immunotherapy Zinc ions exert an essential character in a vast array of physiological and cellular processes, including activation of matrix metalloproteinases, cell proliferation, development, metabolism, DNA biosynthesis and transcription, and PCD. Zinc ions also are involved in protection from oxidation stress, inflammation response, and immune regulation.5 Transportation of zinc ions across cytomembranes is regulated by the cooperation of zinc transporter proteins, known as zinc transporter family or Zrt/Irt-like proteins (ZIPs). ZIPs are responsible for influx of zinc ions from the extracellular compartment or intracellular organelles into cytoplasm, while zinc transporters take charge of zinc ion efflux from Figure 6 Schematic illustration of the underlying therapeutic mechanism of manganese-doped calcium sulfide nanoparticles for cancer cell pyroptosis and cGASSTING pathway activation. (a) The mechanism of pyroptosis and activation of the cGAS-STING signaling pathway triggered by manganese-doped calcium sulfide nanoparticles. (b) H2S strengthened the adaptive immune response. (c) H2S amplified the innate immune response. (d) Reshaping of the immunosuppressive tumor , inhibition. (Reprinted with permission from Lin Liu et al (2024). Copyright (2024) American microenvironment.134 , downregulation; , upregulation; Chemical Society). International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16075 Cheng et al cytoplasm to extracellular compartment or intracellular organelles.136 Given their essential characters in physiological and cellular processes, it necessitates stringent control of zinc ions homeostasis. Zinc Triggered PCD Zinc ion-elicited apoptosis is regulated by promotion of B-cell lymphoma-2 associated X protein (Bax) expression which triggers the liberation of cytochrome C and activation of caspase 3, eventually leading to apoptosis.137 An increase in the ratio of Bax to B-cell lymphoma-2 contributes to deterioration of hypoxia inducible factor-1α followed by decreased expression of the inhibitor of survivin, ultimately triggering apoptosis.138 Also zinc ions can strengthen the expression of Smad2 and PIAS1 as transcription activator 1, followed by activation of P21 gene expression and promotion of apoptosis.139 ZIP9, a zinc transporter protein and membrane androgen-binding receptor, is revealed to be associated with apoptosis via activating G protein.140 In cancer development, lysosomal function is usually upregulated to satisfy the enhanced energy requirement for rapidly proliferating tumor cells.141 Transient receptor potential mucolipin 1, a cation channel with dual permeability to calcium and zinc ions, is upregulated in certain cancer cells and can be activated to trigger lysozincrosis via release of zinc ions from lysosomes, mitochondrial swelling and impairment, and energy depletion.142 Moreover, normal cells expressing low level of transient receptor potential mucolipin 1 are not susceptible to lysozincrosis, indicating its possibility for cancer therapy. Autophagy, a conserved catabolic process, is triggered in response to stress such as energy deprivation, hypoxia, infection, and ER stress and results in degradation of intracellular components.143 Multiple studies consistently indicated that zinc triggers autophagy; however, the mechanisms are still poorly clarified. Extracellular-signal-regulated kinase 1/2 (ERK1/2), metal responsive transcription factor-1 (MTF1), and calcium/calmodulin-dependent protein kinase kinase-B/ AMP-activated protein kinase (CaMKKb/AMPK) are involved in induction of autophagy by zinc.143 Zinc ions are also responsible for triggering necroptosis,144 ferroptosis145 and pyroptosis.146 The mechanism for Zn2+ induced PCD is summarized in Figure 7. Zinc Triggered PCD and Cancer Immunotherapy Zinc ions can enhance the activity of an array of immune cells, including T cells, B cells, and natural killer cells; can polarize macrophages into the M1 phenotype; and alleviate the immunosuppressive state of microenvironment through inhibiting release of inflammatory molecular and inflammatory response. Zinc ions can enhance tumor antigen presenta­ tion and recognition of antigen by immune cells and suppress immune checkpoint protein expression to reinforce an anticancer immune response.147 Zinc ions have emerged as an immunologic adjuvant to activate the cGAS-STING signaling pathway in initiation of anticancer immunity and transformation of a “cold” tumor into a “hot” one.148 Zinc ion-modulated ferroptosis increases the potency of immune cells such as T cells or macrophages, which is related to the release of DAMPs and interferon γ.145 Excess zinc ion-triggered tumor cell pyroptosis also resulted in liberation of mass DAMPs.147 Autophagy and necroptosis also lead to the liberation of DAMPs, activation of immune cells, and antigen presentation.149 Therefore, the combination of zinc ions and cancer immunotherapy can enhance the response rate. Zinc-Based Nanoparticles Enhance Cancer Immunotherapy Overexposure of zinc can damage the nervous system,150 and the targeted delivery of zinc is highlighted to reduce its toxicity. Nanoparticles for delivering Zn ions or zinc-based nanovehicles to boost cancer immunotherapy are shown in Table 5. Sun et al fabricated an erythrocyte membrane-decorated zinc-phenolic nanocapsule for delivery of mitoxantrone and antibody against PD-L1 to treat triple-negative breast cancer with limit immune response. The zinc-phenolic nanocapsule triggered cancer cell pyroptosis, activated the cGAS-STING pathway, and amplified the efficacy of anti-PD-L1 antibody, achieving sustained immune response.151 Zhu et al synthesized ferritin heavy chain siRNA and hyaluronic acid warped arginine-stabilized zinc peroxide to induce Fe2+ overload and ferroptosis, and the liberated Zn2+ induced mitochondrial dysfunction and oxidative stress to further boost ferroptosis. The nanoagent-regulated ferroptosis exerted a potent 16076 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al Figure 7 Schematic illustration of a representative signaling pathway for zinc ion-induced PCD. (reproduced with permission from Yawen You et al (2025). Copyright 2025 Royal Society of Chemistry). , upregulation. immunogenic response for T-cell activation and infiltration, and integration of the nanoagent with anti-PD-1 antibody resulted in prominent anticancer efficacy in vivo.152 A polydopamine-coated zinc-copper bimetallic nanoplatform was introduced to spontaneously liberate Cu2+, Zn2+, and H2O2 in the acidic TME, leading to irreversible cuproptosis and cGAS-STING pathway activation. The zinc-copper bimetallic nanoplatform induced DCs maturation, T cell activation, and PD-L1 expression, sensitizing triple-negative breast cancer to antibody against PD-L1 therapy.153 Lu et al fabricated hyaluronic acid-modified zinc peroxide-iron nanocomposites to reshape the TME and simultaneously trigger pyroptosis and ferroptosis, significantly enhancing the anticancer immune response to anti-PD-1 antibody.154 Bioactive zinc-nickel hydroxide nanosheets initiated zinc overload-regulated pyroptosis, and the released Ni2+ amplified pyroptosis through concurrently inducing paraptosis, inhibiting autophagic flux, and triggering release of endogenous zinc ions. The nanosheets triggered liberation of DAMPs from cancer cells, followed by stimulation of DCs maturation, increase in CD8+ T cell infiltration, and transformation of macrophages to M1 phenotype, strengthening the therapeutic potency of the antibody against PD-1.155 A bovine serum albumin nanocluster was constructed via an ion diffusion approach for co-delivery of zinc and sulfur to enhance cancer immunotherapy as demonstrated in Figure 8. The released zinc ions in a low pH TME prominently enhanced the cGAS-STING pathway. H2S produced by the nanocluster further facilitated production of ROS by zinc ions via specifically inhibiting catalase in hepatocellular carcinoma cells, leading to further activation of cGAS-STING by the accumulated ROS. The nanocluster promoted infiltration of CD8+ T cells into the tumor and cross-presentation of DCs, and integration of the nanocluster and PD-L1 antibody resulted in a significant inhibiting effect on tumor growth and potent immune response.156 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16077 https://doi.org/10.2147/IJN.S558247 Cheng et al 16078 Table 5 Zinc-Based Nanomedicines to Boost Cancer Immunotherapy International Journal of Nanomedicine 2025:20 Carrier Type Payload Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Nanocapsule Mitoxantrone, antiPD-L1 antibody Zinc-phenolic nanocapsule, tannic acid, 8-arm-PEG–OH, erythrocyte membrane ~160 Pyroptosis, STING activation iv Infiltration of cytotoxic T cells, inhibition of suppressive immune cells proliferation, increment of memory T cells in tumor and spleen, and effective inhibition of metastatic tumor growth. [151] Nanocomplex Ferritin heavy chain siRNA Arg-stabilized zinc peroxide, hyaluronic acid ~190 Ferroptosis, enhanced lipid peroxidation production, inhibition of mitochondrial function, ICD, activation and infiltration of T-cell. iv Induction of a strong antitumour immune response, and potentiation of anti-PD-1 antibody efficacy. [152] Nanoparticle None Zinc-copper bimetallic nanoparticle, polyvinylpyrrolidone, polydopamine 177.2 Photothermal therapy, cuproptosis, cGAS-STING activation, reversal of immunosuppressive TME, and upregulation of PD-L1. it Co-administrated with PD-L1 antibody, markedly bolstered anti-tumor immunity and inhibition of tumor growth and metastasis. [153] Nanoparticle None Zinc peroxide-iron nanocomposite, hyaluronic acid, polyvinylpyrrolidone 220 Reshaping tumor stromal microenvironment, pyroptosis, ferroptosis, ICD. iv In combination with PD-1 antibody, prevention of T cells exhaustion and activation of immune response, and potentiation of PD-1 antibody efficacy. [154] Nanosheet None Zinc-nickel hydroxide nanosheet Diameter 200, thickness 11 nm Zinc overload-mediated pyroptosis, paraptosis, ICD. it Activation of immune response, and significant augmentation of PD-1 antibody efficacy. [155] Nanocluster ZnS Bovine serum albumin 100 cGAS/STING activation, apoptosis, promotion of CD8+ T cells infiltration and DCs cross-presentation. iv Facilitation of systemic immune responses, a potential to prevent tumor relapse and metastases. Combined with PD-L1 antibody, significant inhibition of tumor growth. [156] Abbreviations: iv, intravenous injection; it, intratumoral injection. Powered by TCPDF (www.tcpdf.org) Cheng et al Figure 8 Schematic and characteristics of a bovine serum albumin nanocluster for co-delivery of zinc and sulfur. (a) The therapeutic process of the nanoclusters. (b) The synthesis routine of the nanoclusters. (c) Scanning electron microscopy image of the nanoclusters. Scale bar: 1 µm. Inset: High-resolution transmission electron microscopy image. Scale bar: 20 nm. (d) Hydrodynamic size of the nanoclusters in different solutions. (e) X-ray diffraction pattern of the nanoclusters. (f) Element mapping of the nanoclusters. Scale bar: 200 nm. (g) Release profile of H2S from nanoclusters in solutions with different pH of 7.4, 6.5, and 6.0 (n = 3, mean ± standard deviation). , upregulation; , the following step. (reproduced with permission from Xiujun Cai et al (2021). Copyright 2021 John Wiley and Sons). International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16079 Cheng et al Manganese-Based Nanoparticles and Cancer Immunotherapy Manganese, an indispensable trace element in the human body, participates in a vast array of physiologic processes such as serving as a cofactor for various enzymes, development, metabolism, hematopoiesis, protein and vitamin synthesis, endocrine regulation, protection from ROS, and redox homeostasis.5,157 In recent decades, manganese has been used as an inducer for PCD and enhancer for immune function. Manganese-Dependent Cell Death Manganese ions downregulate system Xc− and excitatory amino acid transporter, and cystine as a precursor for GSH biosynthesis is reduced, leading to depletion of GSH and its synthesis.158,159 Blocking the biosynthesis of GSH resulted in excessive accumulation of ROS followed by lipid peroxidation overproduction, and ultimate cell death.160,161 Manganese ions catalyze Fenton-like and Haber-Weiss reactions that produce ROS and exhaust GSH, similar to the iron-triggered Fenton reaction.157 Manganese ions catalyze a Fenton-like reaction in the presence of H2O2 to generate ·OH. Manganese ions also increase mitochondrial H2O2 by fostering superoxide dismutase 2 activity, and releasing oxidoreductases from the Krebs cycle through triggering permeability transition.162,163 Cellular uptake of manganese and iron ions is competitive, and several transporters responsible for iron ions transportation, such as DMT1, TFR, ferroportin, and ferritin, also deliver manganese ions.164–166 Manganese ions disturb iron homeostasis through over-expression of TfR and upregulation of iron uptake in the brain, leading to significantly increased cellular levels of labile iron rather than total cellular iron levels.167–169 Manganese ions trigger ferroptosis in dopaminergic neurons by regulating the hypoxia-inducible factor-1 α /p53/ SLC7A11 signaling pathway.170 Manganese ions drive ferroptosis in oral squamous cell carcinoma cells via nuclear translocation of Yes-associated protein/transcriptional co-activator with PDZ-binding motif and subsequent ACSL4 activation.171 Manganese ions at high concentration trigger cytochrome C liberation from mitochondria and caspase-8 regulated apoptosis in B cells. In neuronal cells, manganese ion-induced apoptosis is facilitated by transcriptional activation of caspase 3, which is induced by phosphorylation of zinc finger transcription factor SP-1.172 Manganese ions can inhibit the acetylation of histone H3 and H4 by augmenting the activity of histone deacetylase and decreasing that of histone acetyltransferase, which eventually triggers apoptosis.173 Manganese ions induce apoptosis through p53- and p38mitogen-activated protein kinases and the mitogen and stress response kinase-1 signaling pathway.174,175 Manganese ions trigger necrosis through ROS-induced lysosomal membrane permeabilization and release of cathe­ psin D into the cytosol, and also via ROS-triggered DNA damage, translocation of apoptosis-inducing factor from mitochondria to the nucleus, and parthanatos.176 Manganese ions also induce necroptosis in macrophages infected with Mycobacterium tuberculosis through the STING-tumor necrosis factor signaling pathway.177 Manganese-Regulated Cancer Immunotherapy Manganese ions exert vital roles in activation and functional regulation of immune cells including T cells, macrophages, and natural killer cells, and they play a role in cancer immunotherapy.147 Manganese ions potently enhance the affinity of cGAS to its agonist DNA substrates, and cGAS is activated by combination with DNA, leading to enzymatic production of cGAMP and activation of STING downstream signaling.178,179 The activated cGAS-STING pathway leads to generation of type I interferons and a vast array of pro-inflammatory cytokines, resulting in enhanced immune surveillance, cytotoxicity of natural killer cells and macrophages, and activation and proliferation of T cells.80,180 Manganese ions modulate the function and upregulate the expression of costimulatory molecules on the membrane of antigen-presenting cells, boost T cell infiltration and survival in the TME, and enhance the strength of natural killer cells and their release of cytokines.147 Although the mechanisms of manganese ions regulated tumor immunotherapy are not fully elucidated, previous studies have explored their clinical value. In a Phase I clinical trial, patients were administered different dose of manganese chloride intranasally or by inhalation in combination with PD-1 antibodies and chemotherapy. After a median 16080 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al follow-up of 11.8 months, the combined protocol exhibited manageable side effects and prominent potency across various tumor types including ovarian, breast, and pancreatic cancers, achieving a disease control rate of 90.9%.80 Manganese-Based Nanoparticles Enhance Cancer Immunotherapy Clinical application of manganese is significantly hindered by its neurotoxicity and non-specific distribution,181 and targeted delivery is of great importance to minimize neurotoxicity. As presented in Table 6, an array of nanoagents delivering manganese ions or manganese-based nanovehicles have been introduced to amplify the immune response and have been integrated with immunotherapy for cancer treatment. A manganese-phenolic network platform was based on doxorubicin carrying PEG-poly(lactic-co-glycolic acid) nanoparticles and further modified by manganese-tannic acid. Manganese triggered a Fenton-like reaction and enhanced anti-tumor immunity by amplifying the cGAS-STING pathway, and integrated therapy of the nanodrug with CTLA-4 blocking antibody exerted superior treatment efficacy to monotherapy.182 Sun et al fabricated hollow mesoporous silicacoated MnO nanoparticles with conjugated iRGD peptide and applied them for cGAS-STING pathway-amplified immunotherapy, a Fenton-like reaction, and T1-weighted magnetic resonance imaging. Integrated MnO nanoparticles and anti-PD-1 antibody enhanced tumor inhibition and activated the immune response.183 PEG-coated manganese molybdate nanoparticles depleted highly accumulated GSH in a tumor and inhibited GPX4 expression, triggering ferroptosis. The manganese molybdate nanoparticles induced release of DAMPs, promoted DCs maturation and T cell infiltration, and reversed the immunosuppressive microenvironment, reprogramming “cold” tumors to “hot” ones. Integration with antibody against PD-L1 further enhanced anti-tumor efficacy and inhibited metastasis.184 As illustrated in Figure 9, a hydrogen peroxide/ultrasound-propelled mesoporous manganese oxide nanomotor was fabricated to load mitochondrial sonosensitizers into mesoporous channels, and their surface was dual-functionalized with silk fibroin and chondroitin sulfate. Mn2+ ions regulated a Fenton-like reaction that decomposed excess H2O2 in the TME into oxygen and toxic hydroxyl radicals. The nanomotor effectively depleted intracellular GSH to downregulate GPX4, a vital regulator for ferroptosis, leading to accumulation of LPO as the hallmark for ferroptosis. The integrated Mn2+ and ultrasound promoted maturation of DCs and T cell-mediated immune response. Integration of the manganese oxide nanomotor and PD-L1 checkpoint inhibitor potently restrained primary tumor growth and prevented tumor recurrence by potentiating systemic anticancer immunity and providing long-term immune memory.185 Risedronate-manganese nano­ belts were fabricated via coordination-driven self-assembly and exerted an outstanding Fenton-like catalytic property and amplified radiotherapy-regulated oxidative stress. The released Mn2+ further activated the cGAS-STING pathway, boosting the efficacy of anti-PD-L1 antibody against primary and metastatic tumors.186 Ultrathin manganese-based layered double hydroxide nanosheets delivering cytokine interferon γ were synthesized to strengthen ferroptosis and systemic anti-tumor immunity. Manganese ion-induced ferroptosis was further boosted by the loaded interferon γtriggered downregulation of SLC7A11, which is responsible for uptake of cystine into cells for GSH biosynthesis. The released manganese ions activated the cGAS-STING signaling pathway and stimulated DCs maturation and T cell infiltration. Endogenous interferon γ secreted by activated CD8+ T cells promoted a cascade of immunogenic ferroptosis, forming a closed-loop treatment. Integrated nanosheets and antibody against PD-L1 achieved a potent abscopal effect on inhibition of both primary and distant tumors.187 A dendrobium polysaccharide hydrogel embedded with Mn2+-pectin microspheres induced apoptosis in cancer cells, activating the cGAS-STING signaling pathway and initiating a cascade of anti-tumor immune responses. The hydrogel generated a synergistic potency with anti-PD1 antibody to inhibit metastasis and abscopal brain tumor proliferation.188 A PEG-modified Mn2+-based MOF delivering paclitaxel induced pronounced apoptosis and promoted maturation of DCs and infiltration of T lymphocytes by activating the cGAS-STING pathway, enhancing the potency of anti-PD-L1 antibody.189 Alginate microspheres embedded in a Pluronic F-127 matrix as a vehicle for Mg2+ and Mn2+ formed a hybrid hydrogel that elicited apoptosis and converted a “cold tumor” to a “hot tumor”, augmenting the therapeutic efficacy of antibody against PD-L1.190 Zhou et al developed manganese-enriched zinc peroxide nanoparticles for synergistic anticancer immunotherapy. The nanoparticles elicited apoptosis, activated the STING pathway, and decreased the immunosuppressive TME. Integrated with PD-1 checkpoint blockage, the nanoparticles demonstrated potent inhibi­ tion of tumor growth and metastasis.191 A tumor cell membrane containing multienzyme-mimicking manganese oxide International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16081 https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Carrier Type Payload Composition Particle Size (nm) Mechanism of Action Administration Outcome Ref. Nanoparticle Doxorubicin PEG-poly(lactic-coglycolic acid), manganese-tannic acid network 70 Chemotherapy, chemodynamic therapy, ICD, amplifying STING signal. iv Remarkable promotion of DCs maturation and CD8+ T cell infiltration. Combined with CTLA-4 antibody, significant inhibition of tumor growth and lung metastasis. [182] Nanoparticle None MnO nanoparticle, hollow mesoporous silica, iRGD peptide 132 Activation of cGAS-STING pathway, immunotherapy, Fenton-like reaction. iv Synergized with PD-1 antibody, high elicitation of cytotoxic T lymphocyte infiltration and restriction of melanoma progression and metastasis. [183] Nanoparticle None Manganese molybdate nanoparticle, DSPEPEG5000 30 Ferroptosis, ICD, release of DAMPs, promotion of DCs maturation, T cells infiltration, and reversal of immunosuppressive microenvironment. it In combination with PD-L1 antibody, enhanced anti-tumor effect and inhibition of metastases. [184] Hydrogel embedding nanoparticle None Chitosan/alginate hydrogel, mesoporous manganese oxide, regenerated silk fibroin, chondroitin sulfate 212.3 Ferroptosis, sonodynamic therapy, chemodynamic therapy, ICD and reversion of immunosuppressive TME. oral Together with PD-L1 antibody, simultaneous suppression of primary and distal tumors. [185] Nanobelt None Risedronate-manganese nanobelt Length 180, width 5 Fenton-like catalytic activity, ICD, inhibition of hypoxia-inducible factor-1α/vascular endothelial growth factor axis and activation of cGAS/ STING pathway. iv Synergized with PD-L1 antibody, inhibition of both in situ and metastatic tumor growth. [186] Nanosheet Interferon γ Ultrathin manganesebased layered double hydroxide nanosheets Diameter 58, thickness 2.28 Ferroptosis, ICD, facilitation of DCs maturation and priming T cells. iv Potent abscopal effect in growth inhibition of primary and distant tumors [187] Hydrogel embedding microsphere Mn2+ Dendrobium polysaccharide, polyvinyl alcohol, pectin ~80 ICD, activation of cGAS-STING, induction of M1 polarization for macrophages, DCs maturation, antigen presentation and T cell-mediated tumor cell killing. implantation Significant inhibition of residual tumor growth and metastasis. Combined with PD-1 antibody, superior therapeutic potency in inhibiting metastasis and abscopal brain tumor. [188] MOF Paclitaxel Mn2+ based MOF, PEG 77.44 ICD, normalization of tumor blood vessels, alleviation of hypoxia, activation of cGAS-STING, promotion of DCs maturation and cytotoxic T lymphocytes infiltration. iv Integrated with PD-L1 antibody, enhanced tumor suppression and prolonged survival in mice. [189] Microsphere-encapsulated hydrogel Mg2+, Mn2+ Pluronic F-127 hydrogel, alginate microspheres Apoptosis, increment of T cells and natural killer cells infiltration, hindrance of myeloid-derived suppressor cells recruitment, modulation of immune checkpoints expression and reshaping TME. it Augment of immune checkpoint blockade efficacy. In conjunction with PD-L1 antibody, potential to reduce tumor recurrence. [190] Powered by TCPDF (www.tcpdf.org) Cheng et al 16082 Table 6 Manganese-Based Nanomedicines to Amplify Cancer Immunotherapy International Journal of Nanomedicine 2025:20 Nanoparticle Mn2+ ZnO2 nanoparticle, polyvinylpyrrolidone 30–50 ICD, activation of STING pathway, priming T cell maturation and expansion, downregulation of Tregs and polarization of M2 macrophages to the M1. iv In combination with PD-1 antibody, superior efficacy in inhibiting tumor growth and preventing lung metastasis. [191] Nanoparticle None Manganese oxide nanoparticle, 4T1 cells membrane 159.31 Apoptosis, ICD, promotion of DCs maturation and M1 repolarization for macrophages, reversal of immunosuppressive TME, and hypoxia relief. iv Together with PD-1 antibody, a robust tumorspecific T cell-mediated anti-tumor response, inhibition of primary and metastatic tumors, and induction of a long-term immune memory. [192] Nanoparticle Peroxydisulfate Mn2Al1 layered double hydroxide nanoparticles 80 Necroptosis, ICD, activation of STING pathway. it Potent activity in inhibiting tumor growth and lung metastasis. Combined with PD-L1 antibody, significant inhibition of distant tumors. [193] Abbreviations: iv, intravenous injection; it, intratumoral injection. 16083 Cheng et al https://doi.org/10.2147/IJN.S558247 Powered by TCPDF (www.tcpdf.org) Cheng et al Figure 9 Schematic illustration of a hydrogen peroxide/ultrasound-propelled mesoporous manganese oxide nanomotor to achieve efficient mucus-traversing ability, deep , blockade. (reproduced with permission from tumor penetration, high anti-tumor efficacy, and potentiation of anti-tumor immunity. , downregulation; , upregulation; Yingui Cao et al (2022). Copyright 2022 John Wiley and Sons). nanozymes induced apoptosis in cancer cells, and the released Mn2+ ions promoted maturation of DCs and M1 repolarization of macrophages by activating the STING pathway. With the support of PD-1 checkpoint blockade, robust anti-tumor immune response and long-term immune memory were achieved, and the growth of primary tumor and metastasis was prominently inhibited.192 An in situ vaccine was fabricated by intercalating peroxydisulfate, a precursor of SO4·-, into manganese layered double hydroxide nanoparticles. Mn2+ mediated peroxydisulfate degradation through Fenton-type advanced oxidation in the tumor to produce in situ SO4·-, which elicited necroptotic cell death and adaptive immunity. The in situ vaccine activated the STING pathway to further enhance anticancer immunity. When integrated with anti-PDL1 antibody, remarkable inhibition of distant tumors was realized.193 16084 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al Perspectives Cancer is responsible for high morbidity and mortality rates and is a prominent health burden worldwide. In recent decades, immunotherapy has emerged as a vital treatment for cancer following chemotherapy, surgical treatment, radiotherapy, and targeted therapy. Patients can benefit from a range of immunotherapeutic approaches including immune checkpoint inhibitors, CAR-T cell therapy, antibody-drug conjugate, cytokine therapy, and vaccination. Despite its great potential, cancer immunotherapy is confronted with significant challenges, and low response rates are a considerable hurdle. Excessive intracellular accumulation of several metal ions, such as Fe2+, Cu2+, Ca2+, Zn2+, and Mn2+, is important for regulating PCD through various signaling pathways. PCD is capable of reprogramming the immunosuppressive TME and inducing immunostimulatory responses,7,8 indicating it as a viable option to enhance the potency of cancer immunotherapy. With advancement of nanotechnology, metal ions are used more extensively in cancer therapy, and efficacy of immunotherapy has been increased. However, issues in academic investigation and clinical application remain to be solved. The precise mechanisms and signaling pathway for metal ion-mediated PCD and enhanced immune response by PCD have not been fully elucidated, and in-depth molecular mechanism study should be performed. The metabolism and longterm safety of metal ions and metal-based nanomaterials are unknown, and further investigation is required. Moreover, optimization of material formulations and development of more biocompatible nanomaterials are needed. One key limitation of this review is insufficient assessment of metabolism and long-term safety of the proposed nanodrugs. Tumor heterogeneity has emerged as a mediator for the efficacy of immunotherapy.194 However, this characteristic spatially and temporally evolves, and it is relatively complex and insufficiently characterized.195 The influential factors affecting response to immunotherapy are complicated rather other only induction of PCD. Integrated strategies to overcome or minimize the detrimental impacts of tumor heterogeneity on immunotherapy and triggers of PCD for achievement of personalized treatment are promising research directions. Additionally, in design of nanomaterials delivering metal ions or metal-based nanovehicles, druggability should be considered. The pharmaceutical industry operates on the “keep it simple, stupid” principle, and complicated manufactur­ ing processes and standardization issues restrict up-scaling of nanodrugs from laboratory to industry scale. In 2025, Clinicaltrials.gov retrieved no ongoing or completed clinic trials about metal ions and cancer immunother­ apy. This is likely due to challenges in large-scale manufacturing and concerns regarding the safety of nanoparticle-based systems. Comprehensive preclinical data on safety and efficacy in large-scale animal tumor xenograft models are essential for successful clinical translation. To improve the prospect of clinical translation, simple and biocompatible nanosystems for loading metal ions and metal-based nanodrugs should be fabricated. Controlled clinical trials are needed to define the limitations and effectiveness of nanomaterials for metal ions in cancer immunotherapy. Conclusion In conclusion, there are challenges for cancer immunotherapy, and leverage of PCD induced by metal ions to amplify efficacy of immunotherapy has demonstrated encouraging achievements in scientific research. Simpler and safer nanocarriers are expected for personal treatment based on research in PCD and tumor heterogeneity, and translation of such methods into clinic is expected to be realized in the near future, along with patients benefit from immunotherapy. Abbreviations ACSL4, acyl-CoA synthetase long-chain family member 4; ATP7A/B, ATPase copper transporting α/β; Bax, B-cell lymphoma-2 associated X protein; BID, BH3 interacting domain death agonist; CaMKKb/AMPK, calcium/calmodulindependent protein kinase kinase-B/AMP-activated protein kinase; CAR-T, chimeric antigen receptor T; cGAS-STING, cyclic GMP-AMP synthase-stimulator of interferon genes; CoA, coenzyme A; CTLA-4, cytotoxic T lymphocyteassociated protein 4; CTR1, copper transporter protein 1; DAMPs, damage-associated molecular patterns; DCs, dendritic cells; DLAT, dihydrolipoamide S-acetyltransferase; DMT1, divalent metal transporter 1; ER, endoplasmic reticulum; ERK1/2, extracellular-signal-regulated kinase; Fe3+, ferric ion; GSH, glutathione; GPXs, glutathione peroxidases; HMGB1, high mobility group box 1; ICD, immunogenic cell death; iRGD, CRGDKGPD peptide; LIP, labile iron International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16085 Cheng et al pool; MLKL, mixed lineage kinase domain-like protein; LMP, lysosomal membrane permeabilization; LOX, lipoxy­ genases; LPCAT3, Lysophosphatidylcholine acyltransferase 3; MOF, metal-organic framework; MT, metallothionein; MTF1, metal responsive transcription factor-1; mTOR, mammalian target of the rapamycin; NCOA4, nuclear receptor coactivator-4; PCD, programmed cell death; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PEG, polyethylene glycol; PUFA, polyunsaturated fatty acids; RIPK, receptor-interacting protein kinase; ROS, reactive oxygen species; TAMs, tumor-associated macrophages; TF, transferrin; TFR1, transferrin receptor 1; TMCO1, transmembrane and coiled-coil domains 1; TME, tumor microenviroment; SLC31A1, solute carrier family 31 member 1; STEAP3, six-transmembrane epithelial antigen of prostate 3; ZIPs, Zrt/Irt-like proteins. Ethics Approval This article does not contain any studies with human participants. Acknowledgment The Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education supported this research (2022M3H4A1A03067401). This research was also supported by a grant by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (RS-2023-00265981), and by a Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (2023R1A6C103A026). This work was also supported by the National Natural Science Foundation of China (81503010). Scheme 1 was created by BioRender.com. Disclosure The authors have no known competing financial interests or personal relationships that could have influenced the work reported in this paper. References 1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–3030. doi:10.1002/cncr.33587 2. G.B.D.C. Collaborators. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023. Lancet. 2025. 3. Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25(5):379–395. doi:10.1038/s41580-023-00689-6 4. Lu JL, Yu CX, Song LJ. Programmed cell death in hepatic fibrosis: current and perspectives. Cell Death Discov. 2023;9(1):449. doi:10.1038/ s41420-023-01749-8 5. Luan M, Feng Z, Zhu W, et al. Mechanism of metal ion-induced cell death in gastrointestinal cancer. Biomed Pharmacother. 2024;174:116574. doi:10.1016/j.biopha.2024.116574 6. You Y, Guo Z, Wolter T, Hu Q. Intracellular metal ion-based chemistry for programmed cell death. Chem Soc Rev. 2025;54(3):1552–1582. doi:10.1039/d4cs00930d 7. Hsu SK, Li CY, Lin IL, et al. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 2021;11(18):8813–8835. doi:10.7150/thno.62521 8. Liu J, Hong M, Li Y, Chen D, Wu Y, Hu Y. Programmed cell death tunes tumor immunity. Front Immunol. 2022;13:847345. doi:10.3389/ fimmu.2022.847345 9. Sun G, He L. A new paradigm for cancer immunotherapy: targeting immunogenic cell death-related noncoding RNA. Front Immunol. 2024;15:1498781. doi:10.3389/fimmu.2024.1498781 10. Ahn W, Han J, Kim N, et al. Hierarchical protein nano-crystalline hydrogel with extracellular vesicles for ectopic lymphoid structure formation. Biomaterials. 2025;318:123166. doi:10.1016/j.biomaterials.2025.123166 11. Zhu Q, Zhang R, Zhao Z, Xie T, Sui X. Harnessing phytochemicals: innovative strategies to enhance cancer immunotherapy. Drug Resist Updat. 2025;79:101206. doi:10.1016/j.drup.2025.101206 12. Mao C, Deng F, Zhu W, et al. In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy. Nat Commun. 2024;15(1):9723. doi:10.1038/s41467-024-54081-9 13. Xue F, Ren X, Kong C, et al. Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy. Mater Today Bio. 2024;28:101239. doi:10.1016/j.mtbio.2024.101239 14. Cai Y, Xiao H, Xue S, et al. Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy. J Exp Clin Cancer Res. 2025;44(1):35. doi:10.1186/s13046-025-03301-1 15. Xia W, Lv Y, Zou Y, et al. The role of ferroptosis in colorectal cancer and its potential synergy with immunotherapy. Front Immunol. 2024;15:1526749. doi:10.3389/fimmu.2024.1526749 16086 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al 16. Ren X, Luo X, Wang F, et al. Recent advances in copper homeostasis-involved tumor theranostics. Asian J Pharm Sci. 2024;19(5):100948. doi:10.1016/j.ajps.2024.100948 17. Rodriguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12(6):784. doi:10.3390/biom12060784 18. Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y. Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review. J Nanobiotechnol. 2024;22(1):587. doi:10.1186/s12951-024-02859-w 19. Zhang J, Zhang A, Guo Y, et al. Nanoparticle-mediated cuproptosis and photodynamic synergistic strategy: a novel horizon for cancer therapy. Cancer Med. 2025;14(3):e70599. doi:10.1002/cam4.70599 20. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042 21. Zhu J, Zhang Z, Chu Y, et al. Application of nanomaterial-mediated ferroptosis regulation in kidney disease. Int J Nanomed. 2025;20:1637– 1659. doi:10.2147/IJN.S496644 22. Eskander G, Abdelhamid SG, Wahdan SA, Radwan SM. Insights on the crosstalk among different cell death mechanisms. Cell Death Discov. 2025;11(1):56. doi:10.1038/s41420-025-02328-9 23. Conti L, Ciambellotti S, Giacomazzo GE, et al. Ferritin nanocomposites for the selective delivery of photosensitizing ruthenium-polypyridyl compounds to cancer cells. Inorg Chem Front. 2022;9(6):1070–1081. doi:10.1039/D1QI01268A 24. Ryu MS, Zhang DL, Protchenko O, Shakoury-Elizeh M, Philpott CC. PCBP1 and NCOA4 regulate erythroid iron storage and heme biosynthesis. J Clin Invest. 2017;127(5):1786–1797. doi:10.1172/JCI90519 25. Daher R, Karim Z. Iron metabolism: state of the art. Transfus Clin Biol. 2017;24(3):115–119. doi:10.1016/j.tracli.2017.06.015 26. Li LH, Wang KP, Jia RJ, et al. Ferroportin-dependent ferroptosis induced by ellagic acid retards liver fibrosis by impairing the SNARE complexes formation. Redox Biol. 2022;56:102435. doi:10.1016/j.redox.2022.102435 27. Liu LH, Lian N, Shi LQ, Hao ZM, Chen K. Ferroptosis: mechanism and connections with cutaneous diseases. Front Cell Dev Biol. 2023;10. doi:10.3389/fcell.2022.1079548 28. Mou YH, Wang J, Wu JC, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12. doi:10.1186/s13045-019-0720-y 29. Mancias JD, Wang XX, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509(7498):105–+. doi:10.1038/nature13148 30. Yang X, Liu Y, Wang Z, Jin Y, Gu W. Ferroptosis as a new tool for tumor suppression through lipid peroxidation. Commun Biol. 2024;7 (1):1475. doi:10.1038/s42003-024-07180-8 31. Dixon SJ, Winter GE, Musavi LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol. 2015;10(7):1604–1609. doi:10.1021/acschembio.5b00245 32. Stoyanovsky DA, Tyurina YY, Shrivastava I, et al. Iron catalysis of lipid peroxidation in ferroptosis: regulated enzymatic or random free radical reaction? Free Radic Biol Med. 2019;133:153–161. doi:10.1016/j.freeradbiomed.2018.09.008 33. Xie Y, Kang R, Klionsky DJ, Tang D. GPX4 in cell death, autophagy, and disease. Autophagy. 2023;19(10):2621–2638. doi:10.1080/ 15548627.2023.2218764 34. Park JW, Choi JY, Hong SA, et al. Exercise induced upregulation of glutamate-cysteine ligase catalytic subunit and glutamate-cysteine ligase modifier subunit gene expression in Thoroughbred horses. Asian-Australas J Anim Sci. 2017;30(5):728–735. doi:10.5713/ajas.16.0776 35. Badgley MA, Kremer DM, Maurer HC, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85–89. doi:10.1126/science.aaw9872 36. Ashraf A, Jeandriens J, Parkes HG, So PW. Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: evidence of ferroptosis. Redox Biol. 2020;32:101494. doi:10.1016/j.redox.2020.101494 37. Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88. doi:10.1038/s41419-020-2298-2 38. Gao M, Yi J, Zhu J, et al. Role of mitochondria in ferroptosis. Mol Cell. 2019;73(2):354–363e3. doi:10.1016/j.molcel.2018.10.042 39. Angeli JPF, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16(12):1180–1191. doi:10.1038/ncb3064 40. Ganz T. Macrophages and Iron Metabolism. Microbiol Spectr. 2016;4(5). doi:10.1128/microbiolspec.MCHD-0037-2016 41. Kapralov AA, Yang Q, Dar HH, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat Chem Biol. 2020;16(3):278–290. doi:10.1038/s41589-019-0462-8 42. Zhu L, Zhao Q, Yang T, Ding W, Zhao Y. Cellular metabolism and macrophage functional polarization. Int Rev Immunol. 2015;34(1):82–100. doi:10.3109/08830185.2014.969421 43. Choi M, Shin J, Lee CE, et al. Immunogenic cell death in cancer immunotherapy. BMB Rep. 2023;56(5):275–286. doi:10.5483/BMBRep.20230024 44. Angeli JPF, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–414. doi:10.1038/s41568-019-0149-1 45. Yamazaki T, Hannani D, Poirier-Colame V, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21(1):69–78. doi:10.1038/cdd.2013.72 46. Drijvers JM, Gillis JE, Muijlwijk T, et al. Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8(+) T Cells. Cancer Immunol Res. 2021;9(2):184–199. doi:10.1158/2326-6066.CIR-20-0384 47. Rothe T, Gruber F, Uderhardt S, et al. 12/15-Lipoxygenase-mediated enzymatic lipid oxidation regulates DC maturation and function. J Clin Invest. 2015;125(5):1944–1954. doi:10.1172/JCI78490 48. Angeli JPF, Xavier da Silva TN, Schilling B. CD8(+) T cells PUF(A)ing the flames of cancer ferroptotic cell death. Cancer Cell. 2022;40 (4):346–348. doi:10.1016/j.ccell.2022.03.003 49. Kim DH, Kim WD, Kim SK, Moon DH, Lee SJ. TGF-beta1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells. Cell Death Dis. 2020;11(5):406. doi:10.1038/s41419-020-2618-6 50. Zhang T, Luo L, He Q, et al. Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure. Eur J Med Res. 2024;29(1):253. doi:10.1186/s40001-024-01809-4 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16087 Cheng et al 51. Kontoghiorghes GJ. Iron load toxicity in medicine: from molecular and cellular aspects to clinical implications. Int J Mol Sci. 2023;24 (16):12928. doi:10.3390/ijms241612928 52. Bai T, Xue P, Shao S, Yan S, Zeng X. Cholesterol depletion-enhanced ferroptosis and immunotherapy via engineered nanozyme. Adv Sci. 2024;11(38):e2405826. doi:10.1002/advs.202405826 53. Shen L, Yang Z, Zhong Y, et al. Cholesterol targeted catalytic hydrogel fueled by tumor debris can enhance microwave ablation therapy and anti-tumor immune response. Adv Sci. 2025;12(5):e2406975. doi:10.1002/advs.202406975 54. Ma J, Yuan H, Zhang J, et al. An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy. J Control Release. 2024;370:501–515. doi:10.1016/j.jconrel.2024.05.001 55. Hou G, Qian J, Wang Y, et al. Hydrazide/metal/indocyanine green coordinated nanoplatform for potentiating reciprocal ferroptosis and immunity against melanoma. ACS Appl Mater Interfaces. 2023;15(31):37143–37156. doi:10.1021/acsami.3c05580 56. Zhao RR, Wu JH, Tong LW, Li JY, Lu YS, Shao JW. Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dualdrugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis. J Colloid Interface Sci. 2024;660:257–276. doi:10.1016/j.jcis.2024.01.066 57. Jeong SD, Jung BK, Lee D, et al. Enhanced immunogenic cell death by apoptosis/ferroptosis hybrid pathway potentiates PD-L1 blockade cancer immunotherapy. ACS Biomater Sci Eng. 2022;8(12):5188–5198. doi:10.1021/acsbiomaterials.2c00950 58. Qian M, Jiang G, Guo W, Huang R. A biodegradable nanosuspension locally used for inhibiting postoperative recurrence and brain metastasis of breast cancer. Nano Lett. 2024;24(10):3165–3175. doi:10.1021/acs.nanolett.3c05146 59. Han W, Duan X, Ni K, Li Y, Chan C, Lin W. Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy. Biomaterials. 2022;280:121315. doi:10.1016/j.biomaterials.2021.121315 60. Wang S, Guo Q, Xu R, Lin P, Deng G, Xia X. Combination of ferroptosis and pyroptosis dual induction by triptolide nano-MOFs for immunotherapy of melanoma. J Nanobiotechnol. 2023;21(1):383. doi:10.1186/s12951-023-02146-0 61. Zhang K, Ma Z, Li S, et al. Disruption of dual homeostasis by a metal-organic framework nanoreactor for ferroptosis-based immunotherapy of tumor. Biomaterials. 2022;284:121502. doi:10.1016/j.biomaterials.2022.121502 62. Zhou R, Liu Y, Wang Z, et al. Nanoparticle-based MRI-guided tumor microenvironment heating via the synergistic effect of ferroptosis and inhibition of TGF-beta signaling. Adv Healthc Mater. 2023;12(21):e2300176. doi:10.1002/adhm.202300176 63. Li Y, Chen J, Xia Q, et al. Photothermal Fe(3)O(4) nanoparticles induced immunogenic ferroptosis for synergistic colorectal cancer therapy. J Nanobiotechnol. 2024;22(1):630. doi:10.1186/s12951-024-02909-3 64. Jiang Q, Wang K, Zhang X, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small. 2020;16(22):e2001704. doi:10.1002/smll.202001704 65. Liang H, Wu X, Zhao G, Feng K, Ni K, Sun X. Renal clearable ultrasmall single-crystal Fe nanoparticles for highly selective and effective ferroptosis therapy and immunotherapy. J Am Chem Soc. 2021;143(38):15812–15823. doi:10.1021/jacs.1c07471 66. Shen J, Feng K, Yu J, et al. Responsive and traceless assembly of iron nanoparticles and (131)I labeled radiopharmaceuticals for ferroptosis enhanced radio-immunotherapy. Biomaterials. 2025;313:122795. doi:10.1016/j.biomaterials.2024.122795 67. Hu R, Dai C, Dai X, et al. Topology regulation of nanomedicine for autophagy-augmented ferroptosis and cancer immunotherapy. Sci Bull. 2023;68(1):77–94. doi:10.1016/j.scib.2022.12.030 68. Xiang Q, Yang X, Zhang Z, et al. Fe/Mo-based lipid peroxidation nanoamplifier combined with adenosine immunometabolism regulation to augment anti-breast cancer immunity. Adv Mater. 2025;37(8):e2419120. doi:10.1002/adma.202419120 69. Li Z, Rong L. Cascade reaction-mediated efficient ferroptosis synergizes with immunomodulation for high-performance cancer therapy. Biomater Sci. 2020;8(22):6272–6285. doi:10.1039/D0BM01168A 70. Yao X, Yang B, Wang S, et al. A novel multifunctional FePt/BP nanoplatform for synergistic photothermal/photodynamic/chemodynamic cancer therapies and photothermally-enhanced immunotherapy. J Mater Chem B. 2020;8(35):8010–8021. doi:10.1039/D0TB00411A 71. Li J, Zhou Y, Liu J, et al. Metal-phenolic networks with ferroptosis to deliver NIR-responsive CO for synergistic therapy. J Control Release. 2022;352:313–327. doi:10.1016/j.jconrel.2022.10.025 72. Zhang D, Cui P, Dai Z, et al. Tumor microenvironment responsive FePt/MoS(2) nanocomposites with chemotherapy and photothermal therapy for enhancing cancer immunotherapy. Nanoscale. 2019;11(42):19912–19922. doi:10.1039/C9NR05684J 73. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254–1261. doi:10.1126/science.abf0529 74. Maung MT, Carlson A, Olea-Flores M, et al. The molecular and cellular basis of copper dysregulation and its relationship with human pathologies. FASEB J. 2021;35(9):e21810. doi:10.1096/fj.202100273RR 75. Wang L, ChenLiu Z, Wang D, Tang D. Cross-talks of GSH, mitochondria, RNA m6A modification, NRF2, and p53 between ferroptosis and cuproptosis in HCC: a review. Int J Biol Macromol. 2025;302:140523. doi:10.1016/j.ijbiomac.2025.140523 76. Yang Y, Dong C, Ma X, et al. Advances in cuproptosis harnessing copper-based nanomaterials for cancer therapy. J Mater Chem B. 2025;13 (9):2978–2999. doi:10.1039/D4TB02746A 77. Dreishpoon MB, Bick NR, Petrova B, et al. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. J Biol Chem. 2023;299 (9):105046. doi:10.1016/j.jbc.2023.105046 78. Saporito-Magrina CM, Musacco-Sebio RN, Andrieux G, et al. Copper-induced cell death and the protective role of glutathione: the implication of impaired protein folding rather than oxidative stress. Metallomics. 2018;10(12):1743–1754. doi:10.1039/C8MT00182K 79. Xiong C, Ling H, Hao Q, Zhou X. Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ. 2023;30(4):876–884. doi:10.1038/ s41418-023-01125-0 80. Lv M, Chen M, Zhang R, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30(11):966–979. doi:10.1038/s41422-020-00395-4 81. Zheng J, Mo J, Zhu T, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133. doi:10.1186/s12943-020-01250-1 82. Jiang A, Luo P, Chen M, et al. A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. Cell Biosci. 2022;12(1):209. doi:10.1186/s13578-022-00948-7 16088 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al 83. Zhu C, Li J, Sun W, Li D, Wang Y, Shen XC. Signaling mechanism of cuproptosis activating cGAS-STING immune pathway. JACS Au. 2024;4 (10):3988–3999. doi:10.1021/jacsau.4c00712 84. Zeng J, Chen H, Liu X, et al. Cuproptosis in microsatellite stable colon cancer cells affects the cytotoxicity of CD8(+)T through the WNT signaling pathway. Chem Biol Interact. 2024;403:111239. doi:10.1016/j.cbi.2024.111239 85. Lu Y, Fan X, Pan Q, He B, Pu Y. A mitochondria-targeted anticancer copper dithiocarbamate amplifies immunogenic cuproptosis and macrophage polarization. J Mater Chem B. 2024;12(8):2006–2014. doi:10.1039/D3TB02886K 86. Wang Y, Yan Q, Shi Y, Long M. Copper toxicity in animals: a review. Biol Trace Elem Res. 2025;203(5):2675–2686. doi:10.1007/s12011-02404345-8 87. Dai Y, Zhu L, Li X, et al. A biomimetic cuproptosis amplifier for targeted NIR-II fluorescence/photoacoustic imaging-guided synergistic NIR-II photothermal immunotherapy. Biomaterials. 2024;305:122455. doi:10.1016/j.biomaterials.2023.122455 88. Shen W, Pei P, Zhang C, et al. A polymeric hydrogel to eliminate programmed death-ligand 1 for enhanced tumor radio-immunotherapy. ACS Nano. 2023;17(23):23998–24011. doi:10.1021/acsnano.3c08875 89. Wu L, Pi W, Huang X, et al. Orchestrated metal-coordinated carrier-free celastrol hydrogel intensifies T cell activation and regulates response to immune checkpoint blockade for synergistic chemo-immunotherapy. Biomaterials. 2025;312:122723. doi:10.1016/j.biomaterials.2024.122723 90. Xu Y, Wu Y, Zheng X, et al. A smart nanomedicine unleashes a dual assault of glucose starvation and cuproptosis to supercharge alphaPD-L1 therapy. Adv Sci. 2025;12(4):e2411378. doi:10.1002/advs.202411378 91. Ruan Y, Zhuang H, Zeng X, et al. Engineered microbial nanohybrids for tumor-mediated NIR II photothermal enhanced ferroptosis/cuproptosis and immunotherapy. Adv Healthc Mater. 2024;13(4):e2302537. doi:10.1002/adhm.202302537 92. Jing Q, Zhang J, Yuan L, et al. Copper-based hollow mesoporous nanogenerator with reactive oxygen species and reactive nitrogen species storm generation for self-augmented immunogenic cell death-mediated triple-negative breast cancer immunotherapy. J Colloid Interface Sci. 2025;688:688–702. doi:10.1016/j.jcis.2025.02.186 93. Lu X, Deng W, Wang S, et al. PEGylated Elesclomol@Cu(II)-based metal‒organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy. Mater Today Bio. 2024;29:101317. doi:10.1016/j.mtbio.2024.101317 94. Guo B, Yang F, Zhang L, et al. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with alphaPDL1 for enhanced cancer immunotherapy. Adv Mater. 2023;35(22):e2212267. doi:10.1002/adma.202212267 95. Lu X, Chen X, Lin C, et al. Elesclomol loaded copper oxide nanoplatform triggers cuproptosis to enhance antitumor immunotherapy. Adv Sci. 2024;11(18):e2309984. doi:10.1002/advs.202309984 96. Li Y, Liu J, Chen Y, Weichselbaum RR, Lin W. Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy. Adv Sci. 2024;11(23):e2310309. doi:10.1002/advs.202310309 97. Lu S, Li Y, Yu Y. Glutathione-scavenging celastrol-cu nanoparticles induce self-amplified cuproptosis for augmented cancer immunotherapy. Adv Mater. 2024;36(35):e2404971. doi:10.1002/adma.202404971 98. Yu Z, Cao L, Shen Y, et al. Inducing cuproptosis with copper ion-loaded aloe emodin self-assembled nanoparticles for enhanced tumor photodynamic immunotherapy. Adv Healthc Mater. 2025;14:e2404612. doi:10.1002/adhm.202404612 99. Yan C, Liu Y, Zhao G, et al. Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy. Acta Pharm Sin B. 2024;14(5):2281–2297. doi:10.1016/j.apsb.2024.01.017 100. Yan C, Lv H, Feng Y, Li Y, Zhao Z. Inhalable nanoparticles with enhanced cuproptosis and cGAS-STING activation for synergistic lung metastasis immunotherapy. Acta Pharm Sin B. 2024;14(8):3697–3710. doi:10.1016/j.apsb.2024.04.028 101. Gu J, Guo C, Ruan J, et al. From ferroptosis to cuproptosis, and calcicoptosis, to find more novel metals-mediated distinct form of regulated cell death. Apoptosis. 2024;29(5–6):586–604. doi:10.1007/s10495-023-01927-0 102. Zheng SL, Zhao D, Hou GX, et al. iASPP suppresses Gp78-mediated TMCO1 degradation to maintain Ca homeostasis and control tumor growth and drug resistance. Proc Natl Acad Sci U S A. 2022;119(6). doi:10.1073/pnas.2111380119 103. Xiao PT, Li CF, Liu YD, et al. The role of metal ions in the occurrence, progression, drug resistance, and biological characteristics of gastric cancer. Front Pharmacol. 2024;15. doi:10.3389/fphar.2024.1333543 104. Bhosale G, Sharpe JA, Sundier SY, Duchen MR. Calcium signaling as a mediator of cell energy demand and a trigger to cell death. Ann Ny Acad Sci. 2015;1350:107–116. doi:10.1111/nyas.12885 105. He R, Wang ZF, Dong S, Chen Z, Zhou WC. Understanding necroptosis in pancreatic diseases. Biomolecules. 2022;12(6):828. doi:10.3390/ biom12060828 106. Cai ZY, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis (vol 16, pg 55, 2014. Nat Cell Biol. 2014;16(2):200. doi:10.1038/ncb2908 107. Akbulut Y, Gaunt HJ, Muraki K, et al. (–)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Edit. 2015;54(12):3787–3791. doi:10.1002/anie.201411511 108. Sulzmaier FJ, Li ZW, Nakashige ML, Fash DM, Chain WJ, Ramos JW. Englerin A selectively induces necrosis in human renal cancer cells. PLoS One. 2012;7(10):e48032. doi:10.1371/journal.pone.0048032 109. Wu TTL, Peters AA, Tan PT, Roberts-Thomson SJ, Monteith GR. Consequences of activating the calcium-permeable ion channel TRPV1 in breast cancer cells with regulated TRPV1 expression. Cell Calcium. 2014;56(2):59–67. doi:10.1016/j.ceca.2014.04.006 110. Gielecinska A, Kciuk M, Kontek R. The Impact of Calcium Overload on Cellular Processes: exploring Calcicoptosis and Its Therapeutic Potential in Cancer. Int J Mol Sci. 2024;25(24):13727. doi:10.3390/ijms252413727 111. Kim KD, Bae S, Capece T, et al. Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment. Nat Commun. 2017;8. 112. Trebak M, Kinet JP. Calcium signalling in T cells. Nat Rev Immunol. 2019;19(3):154–169. doi:10.1038/s41577-018-0110-7 113. Meng XH, Wu XY, Zheng YY, et al. Exploiting Ca signaling in T cells to advance cancer immunotherapy. Semin Immunol. 2020;49:101434. doi:10.1016/j.smim.2020.101434 114. Gielecinska A, Kciuk M, Yahya EB, Ainane T, Mujwar S, Kontek R. Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents? BBA-Rev Cancer. 2023;1878(6). 115. Ji S, Lee JY, Schrör J, et al. The dialkyl resorcinol stemphol disrupts calcium homeostasis to trigger programmed immunogenic necrosis in cancer. Cancer Lett. 2018;416:109–123. doi:10.1016/j.canlet.2017.12.011 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16089 Cheng et al 116. Guilbaud E, Kroemer G, Galluzzi L. Calreticulin exposure orchestrates innate immunosurveillance. Cancer Cell. 2023;41(6):1014–1016. doi:10.1016/j.ccell.2023.04.015 117. Tufi R, Panaretakis T, Bianchi K, et al. Reduction of endoplasmic reticulum Ca levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ. 2008;15(2):274–282. doi:10.1038/sj.cdd.4402275 118. Chen DG, Xie J, Fiskesund R, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9:873. doi:10.1038/s41467-018-03225-9 119. Liu JT, Wei YH, Jia WB, et al. Chenodeoxycholic acid suppresses AML progression through promoting lipid peroxidation via ROS/p38 MAPK/ DGAT1 pathway and inhibiting M2 macrophage polarization. Redox Biol. 2022;56:102452. doi:10.1016/j.redox.2022.102452 120. Ortiz-Prado E, Vasconez-Gonzalez J, Izquierdo-Condoy JS, et al. Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health. Front Nutr. 2025;12:1579957. doi:10.3389/fnut.2025.1579957 121. Fang TX, Cao XA, Wang L, Chen M, Deng YY, Chen GJ. Bioresponsive and immunotherapeutic nanomaterials to remodel tumor micro­ environment for enhanced immune checkpoint blockade. Bioact Mater. 2024;32:530–542. doi:10.1016/j.bioactmat.2023.10.023 122. Li TX, Zhang YT, Li HY, et al. Bufalin CaCO nanoparticles triggered pyroptosis through calcium overload via Na/Ca exchanger reverse for cancer immunotherapy. Nano Lett. 2024;24(40):12691–12700. doi:10.1021/acs.nanolett.4c04061 123. Chang MY, Hou ZY, Jin DY, et al. Colorectal tumor microenvironment-activated bio-decomposable and metabolizable Cu 2 O@CaCO 3 nanocomposites for synergistic oncotherapy. Adv Mater. 2020;32(43). doi:10.1002/adma.202004647 124. Zheng L, Ding Y, Fang S, et al. Potentiated calcium carbonate with enhanced calcium overload induction and acid neutralization capabilities to boost chemoimmunotherapy against liver cancer. ACS Nano. 2024;18(40):27597–27616. doi:10.1021/acsnano.4c08690 125. Qian R, Yi X, Liu T, et al. Regulation of ion homeostasis for enhanced tumor radio-immunotherapy. Adv Sci. 2023;10(32):e2304092. doi:10.1002/advs.202304092 126. Luo G, Li X, Lin J, et al. Multifunctional calcium-manganese nanomodulator provides antitumor treatment and improved immunotherapy via reprogramming of the tumor microenvironment. ACS Nano. 2023;17(16):15449–15465. doi:10.1021/acsnano.3c01215 127. Dong ZL, Liu Y, Wang CJ, et al. Tumor microenvironment modulating CaCO-based colloidosomal microreactors can generally reinforce cancer immunotherapy. Adv Mater. 2024;36(9). 128. Yan J, Li W, Tian H, et al. Metal-phenolic nanomedicines regulate T-cell antitumor function for sono-metabolic cancer therapy. ACS Nano. 2023;17(15):14667–14677. doi:10.1021/acsnano.3c02428 129. Yu Y, Xie BR, Liu XH, Ye JJ, Zhong Z, Zhang XZ. Mineralized Porphyrin Metal-Organic Framework for Improved Tumor Elimination and Combined Immunotherapy. ACS Nano. 2023;17(13):12471–12482. doi:10.1021/acsnano.3c02126 130. Tan X, Huang J, Wang Y, et al. Transformable nanosensitizer with tumor microenvironment-activated sonodynamic process and calcium release for enhanced cancer immunotherapy. Angew Chem Int Ed Engl. 2021;60(25):14051–14059. doi:10.1002/anie.202102703 131. Cao Z, Yang X, Yang W, et al. Modulation of dendritic cell function via nanoparticle-induced cytosolic calcium changes. ACS Nano. 2024;18 (10):7618–7632. doi:10.1021/acsnano.4c00550 132. Wu JX, Yi SX, Cao YG, et al. Dual-driven nanomotors enable tumor penetration and hypoxia alleviation for calcium overload-photoimmunotherapy against colorectal cancer. Biomaterials. 2023;302:122332. doi:10.1016/j.biomaterials.2023.122332 133. Huang C, Lin B, Chen C, et al. Synergistic reinforcing of immunogenic cell death and transforming tumor-associated macrophages via a multifunctional cascade bioreactor for optimizing cancer immunotherapy. Adv Mater. 2022;34(51):e2207593. doi:10.1002/adma.202207593 134. Liu L, Lei HL, Hou GH, et al. Gas-amplified metalloimmunotherapy with dual activation of pyroptosis and the STING pathway for remodeling the immunosuppressive cervical cancer microenvironment. Acs Nano. 2024;18(20):12830–12844. doi:10.1021/acsnano.4c00017 135. Zhao H, Wang L, Zeng K, Li J, Chen W, Liu YN. Nanomessenger-mediated signaling cascade for antitumor immunotherapy. ACS Nano. 2021;15(8):13188–13199. doi:10.1021/acsnano.1c02765 136. Liu H, Li L, Lu R. ZIP transporters-regulated Zn(2+) homeostasis: a novel determinant of human diseases. J Cell Physiol. 2024;239(5):e31223. doi:10.1002/jcp.31223 137. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. Bmc Cell Biol. 2013;14. doi:10.1186/1471-2121-14-32 138. Ma D, Guo YC, Fu YQ, Wu JF, Ren RM. Temporal relationship of the orphan receptor TR3 translocation and expression with zinc-induced apoptosis in prostate cancer cells. Transl Androl Urol. 2023;12(3):444–454. doi:10.21037/tau-23-61 139. Yang N, Zhao B, Rasul A, Qin H, Li J, Li X. PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis. Cell Death Dis. 2013;4:e811–e811. doi:10.1038/cddis.2013.333 140. Thomas P, Converse A, Berg HA. ZIP9, a novel membrane androgen receptor and zinc transporter protein. Gen Comp Endocrinol. 2018;257:130–136. doi:10.1016/j.ygcen.2017.04.016 141. Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15 (9):642–660. doi:10.1093/procel/pwae003 142. Hadian K, Stockwell BR. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov. 2023;22(9):723–742. doi:10.1038/s41573-023-00749-8 143. Liuzzi JP, Pazos R. Interplay Between Autophagy and Zinc. J Trace Elem Med Bio. 2020;62:126636. doi:10.1016/j.jtemb.2020.126636 144. Zhang L, Liu JT, Dai ZY, et al. Crosstalk between regulated necrosis and micronutrition, bridged by reactive oxygen species. Front Nutr. 2022;9. 145. Gong D, Chen M, Wang Y, Shi J, Hou Y. Role of ferroptosis on tumor progression and immunotherapy. Cell Death Discov. 2022;8(1):427. doi:10.1038/s41420-022-01218-8 146. Vana F, Szabo Z, Masarik M, Kratochvilova M. The interplay of transition metals in ferroptosis and pyroptosis. Cell Div. 2024;19(1). doi:10.1186/s13008-024-00127-9 147. Zhao L, Gui YJ, Cai J, Deng XY. Biometallic ions and derivatives: a new direction for cancer immunotherapy. Mol Cancer. 2025;24(1). doi:10.1186/s12943-025-02225-w 148. Sun X, Zhang Y, Li J, et al. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16(11):1260–1270. doi:10.1038/s41565-021-00962-9 16090 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 International Journal of Nanomedicine 2025:20 Cheng et al 149. Chen Y, Wang Z, Zhang C, Su Y, Zhou T, Hu K. Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy. Front Immunol. 2024;15:1470071. doi:10.3389/fimmu.2024.1470071 150. Elliott ER, Brock KE, Taul AC, et al. The effects of zinc on proprioceptive sensory function and nerve conduction. NeuroSci. 2023;4(4):305– 318. doi:10.3390/neurosci4040025 151. Sun W, Wang H, Qi Y, et al. Metal-phenolic vehicles potentiate cycle-cascade activation of pyroptosis and cGAS-STING pathway for tumor immunotherapy. ACS Nano. 2024;18(34):23727–23740. doi:10.1021/acsnano.4c08613 152. Zhu L, Leng D, Guo Z, et al. Self-catalyzed nitric oxide nanocomplexes induce ferroptosis for cancer immunotherapy. J Control Release. 2025;377:524–539. doi:10.1016/j.jconrel.2024.11.048 153. Zhou B, Chen M, Hao Z, et al. Zinc-copper bimetallic nanoplatforms trigger photothermal-amplified cuproptosis and cGAS-STING activation for enhancing triple-negative breast cancer immunotherapy. J Nanobiotechnol. 2025;23(1):137. doi:10.1186/s12951-025-03186-4 154. Lu Y, Chen Y, Hou G, et al. Zinc-iron bimetallic peroxides modulate the tumor stromal microenvironment and enhance cell immunogenicity for enhanced breast cancer immunotherapy therapy. ACS Nano. 2024;18(15):10542–10556. doi:10.1021/acsnano.3c12615 155. Chen Y, Lu Y, Lei H, et al. Zinc-nickel bimetallic hydroxide nanosheets activate the paraptosis-pyroptosis positive feedback cycle for enhanced tumor immunotherapy. ACS Nano. 2024;18(43):29913–29929. doi:10.1021/acsnano.4c10378 156. Cen D, Ge Q, Xie C, et al. ZnS@BSA nanoclusters potentiate efficacy of cancer immunotherapy. Adv Mater. 2021;33(49):e2104037. doi:10.1002/adma.202104037 157. Kusi D, Sun Y, Liu C. Advances in Manganese-based nanomaterials for cancer therapy via regulating Non-Ferrous ferroptosis. Int J Pharm. 2025;669:125101. doi:10.1016/j.ijpharm.2024.125101 158. Neth K, Lucio M, Walker A, Zorn J, Schmitt-Kopplin P, Michalke B. Changes in brain metallome/metabolome pattern due to a single i.v. Injection of Manganese in rats. PLoS One. 2015;10(9):e0138270. 159. Yang X, Yang H, Wu F, et al. Mn inhibits GSH synthesis via downregulation of neuronal EAAC1 and astrocytic xCT to cause oxidative damage in the striatum of mice. Oxid Med Cell Longev. 2018;2018:4235695. doi:10.1155/2018/4235695 160. Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y. The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther. 2020;13:5429–5441. doi:10.2147/OTT.S254995 161. Shukla K, Thomas AG, Ferraris DV, et al. Inhibition of xc(-) transporter-mediated cystine uptake by sulfasalazine analogs. Bioorg Med Chem Lett. 2011;21(20):6184–6187. doi:10.1016/j.bmcl.2011.07.081 162. Bonke E, Siebels I, Zwicker K, Dröse S. Manganese ions enhance mitochondrial HO emission from Krebs cycle oxidoreductases by inducing permeability transition. Free Radical Bio Med. 2016;99:43–53. doi:10.1016/j.freeradbiomed.2016.07.026 163. Fernandes J, Hao L, Bijli KM, et al. From the cover: manganese stimulates mitochondrial H2O2 production in SH-SY5Y human neuroblastoma cells over physiologic as well as toxicologic range. Toxicol Sci. 2017;155(1):213–223. doi:10.1093/toxsci/kfw196 164. Vogt AS, Arsiwala T, Mohsen M, Vogel M, Manolova V, Bachmann MF. On iron metabolism and its regulation. Int J Mol Sci. 2021;22(9):4591. doi:10.3390/ijms22094591 165. Wang X, Miller DS, Zheng W. Intracellular localization and subsequent redistribution of metal transporters in a rat choroid plexus model following exposure to manganese or iron. Toxicol Appl Pharmacol. 2008;230(2):167–174. doi:10.1016/j.taap.2008.02.024 166. Yin ZB, Jiang HY, Lee ESY, et al. Ferroportin is a manganese-responsive protein that decreases manganese cytotoxicity and accumulation. J Neurochem. 2010;112(5):1190–1198. doi:10.1111/j.1471-4159.2009.06534.x 167. Kwik-Uribe C, Smith DR. Temporal responses in the disruption of iron regulation by manganese. J Neurosci Res. 2006;83(8):1601–1610. doi:10.1002/jnr.20836 168. Zheng W, Zhao Q. Iron overload following manganese exposure in cultured neuronal, but not neuroglial cells. Brain Res. 2001;897(1–2):175– 179. doi:10.1016/S0006-8993(01)02049-2 169. Zheng W, Zhao QQ, Slavkovich V, Aschner M, Graziano JH. Alteration of iron homeostasis following chronic exposure to manganese in rats. Brain Res. 1999;833(1):125–132. doi:10.1016/S0006-8993(99)01558-9 170. Chen J, Tao ZH, Zhang XY, et al. Manganese overexposure results in ferroptosis through the HIF-1α/p53/ SLC7A11 pathway in ICR mouse brain and PC12 cells. Ecotox Environ Safe. 2024;279:116481. doi:10.1016/j.ecoenv.2024.116481 171. Chen H, Cui H, Liu W, et al. Manganese drives ferroptosis of cancer cells via YAP/TAZ phase separation activated ACSL4 in OSCC. Oral Dis. 2024;30(8):4898–4908. doi:10.1111/odi.14925 172. Rozenberg JM, Kamynina M, Sorokin M, et al. The role of the metabolism of zinc and manganese ions in human cancerogenesis. Biomedicines. 2022;10(5):1072. doi:10.3390/biomedicines10051072 173. Guo ZK, Zhang ZP, Wang QQ, et al. Manganese chloride induces histone acetylation changes in neuronal cells: its role in manganese-induced damage. Neurotoxicology. 2018;65:255–263. doi:10.1016/j.neuro.2017.11.003 174. Wan CH, Ma X, Shi SS, et al. Pivotal roles of p53 transcription-dependent and -independent pathways in manganese-induced mitochondrial dysfunction and neuronal apoptosis. Toxicol Appl Pharm. 2014;281(3):294–302. doi:10.1016/j.taap.2014.10.013 175. Mchichi BE, Hadji A, Vazquez A, Leca G. P38 MAPK and MSK1 mediate caspase-8 activation in manganese-induced mitochondria-dependent cell death. Cell Death Differ. 2007;14(10):1826–1836. doi:10.1038/sj.cdd.4402187 176. Alcon SP, Gorojod RM, Kotler ML. Regulated necrosis orchestrates microglial cell death in manganese-induced toxicity. Neuroscience. 2018;393:206–225. doi:10.1016/j.neuroscience.2018.10.006 177. Qian K, Shan L, Shang S, et al. Manganese enhances macrophage defense against Mycobacterium tuberculosis via the STING-TNF signaling pathway. Int Immunopharmacol. 2022;113(Pt B):109471. doi:10.1016/j.intimp.2022.109471 178. Wang C, Guan Y, Lv M, et al. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity. 2018;48(4):675–687e7. doi:10.1016/j.immuni.2018.03.017 179. Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020;21(9):501– 521. doi:10.1038/s41580-020-0244-x 180. Wang C, Sun Z, Zhao C, et al. Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect. J Control Release. 2021;331:480–490. doi:10.1016/j.jconrel.2021.01.036 181. Luo Y, Zhu C, Guo X, et al. Engineering a lipid nanoparticle with atypical calcium crystal structure for enhanced IFNbeta-mediated immunotherapy. Adv Mater. 2025;37:e2419870. doi:10.1002/adma.202419870 International Journal of Nanomedicine 2025:20 Powered by TCPDF (www.tcpdf.org) https://doi.org/10.2147/IJN.S558247 16091 Cheng et al 182. Pang XR, Fu CP, Chen JB, et al. A manganese-phenolic network platform amplifying STING activation to potentiate MRI guided cancer chemo-/chemodynamic/immune therapy. Biomater Sci UK. 2023;11(11):3840–3850. doi:10.1039/D2BM02140D 183. Sun ZL, Wang ZY, Wang T, et al. Biodegradable MnO-based nanoparticles with engineering surface for tumor therapy: simultaneous fenton-like ion delivery and immune activation. Acs Nano. 2022;16(8):11862–11875. doi:10.1021/acsnano.2c00969 184. Lei H, Li Q, Pei Z, Liu L, Yang N, Cheng L. Nonferrous ferroptosis inducer manganese molybdate nanoparticles to enhance tumor immunotherapy. Small. 2023;19(45):e2303438. doi:10.1002/smll.202303438 185. Cao Y, Liu S, Ma Y, et al. Oral nanomotor-enabled mucus traverse and tumor penetration for targeted chemo-sono-immunotherapy against colon cancer. Small. 2022;18(42):e2203466. doi:10.1002/smll.202203466 186. Huang Z, Huang S, Song S, et al. Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy. Nat Commun. 2024;15(1):8692. doi:10.1038/s41467-024-53084-w 187. Liu J, Zhan J, Zhang Y, et al. Ultrathin clay nanoparticles-mediated mutual reinforcement of ferroptosis and cancer immunotherapy. Adv Mater. 2024;36(9):e2309562. doi:10.1002/adma.202309562 188. Gao N, Huang YR, Jing SS, et al. Environment-responsive dendrobium polysaccharide hydrogel embedding manganese microsphere as a postoperative adjuvant to boost cascaded immune cycle against melanoma. Theranostics. 2024;14(10):3810–3826. doi:10.7150/thno.94354 189. Fang MX, Zheng J, Wang JX, et al. Amplifying STING activation and alleviating immunosuppression through a Mn 2+-based metal-organic framework nanosystem for synergistic cancer therapy. Biomater Res. 2024;28. doi:10.34133/bmr.0028 190. Ma L, Wang XY, Wu YX, et al. Controlled release of manganese and magnesium ions by microsphere-encapsulated hydrogel enhances cancer immunotherapy. J Control Release. 2024;372:682–698. doi:10.1016/j.jconrel.2024.06.067 191. Zhou ML, Liang S, Liu D, et al. Manganese-enriched zinc peroxide functional nanoparticles for potentiating cancer immunotherapy. Nano Lett. 2023;23(22):10350–10359. doi:10.1021/acs.nanolett.3c02941 192. Zhao Z, Dong S, Liu Y, et al. Tumor microenvironment-activable manganese-boosted catalytic immunotherapy combined with PD-1 checkpoint blockade. ACS Nano. 2022;16(12):20400–20418. doi:10.1021/acsnano.2c06646 193. Huang Y, Zou J, Huo J, Zhang M, Yang Y. Sulfate radical based in situ vaccine boosts systemic antitumor immunity via concurrent activation of necroptosis and STING pathway. Adv Mater. 2024;36(41):e2407914. doi:10.1002/adma.202407914 194. Oh MS, Abascal J, Rennels AK, Salehi-Rad R, Dubinett SM, Liu B. Tumor heterogeneity and the immune response in non-small cell lung cancer: emerging insights and implications for immunotherapy. Cancers. 2025;17(6):1027. doi:10.3390/cancers17061027 195. Cheng X, Li H, Ge X, et al. Tumor-microenvironment- responsive size-shrinkable drug-delivery nanosystems for deepened penetration into tumors. Front Mol Biosci. 2020;7:576420. doi:10.3389/fmolb.2020.576420 International Journal of Nanomedicine Publish your work in this journal The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http:// www.dovepress.com/testimonials.php to read real quotes from published authors. Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal 16092 Powered by TCPDF (www.tcpdf.org) International Journal of Nanomedicine 2025:20